var title_f20_6_20576="TM air fluid level";
var content_f20_6_20576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tympanic membrane with air-fluid levels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An air-fluid level is appreciated when the tympanic membrane appears translucent above and opaque below a line demarcating the separation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20576=[""].join("\n");
var outline_f20_6_20576=null;
var title_f20_6_20577="Perineal degloving injury";
var content_f20_6_20577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perineal degloving injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complex pelvic fracture with perineal degloving.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20577=[""].join("\n");
var outline_f20_6_20577=null;
var title_f20_6_20578="Sagittal knee anatomy";
var content_f20_6_20578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 391px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of the knee anatomy demonstrating the relationship between the bones, tendons, and bursae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20578=[""].join("\n");
var outline_f20_6_20578=null;
var title_f20_6_20579="Urinary tract infection in renal transplant recipients";
var content_f20_6_20579=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary tract infection in renal transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20579/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20579/contributors\">",
"     Mohamed H Sayegh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20579/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20579/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20579/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20579/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/6/20579/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection (UTI) is the most common bacterial infection occurring in the renal transplant recipient, particularly in the first few months posttransplant. The major risk factors for UTI in the renal transplant recipient include indwelling bladder catheters, handling and trauma to the kidney and ureter during surgery, anatomic abnormalities of the native or transplanted kidneys (such as vesicoureteral reflux, stones, or stents), neurogenic bladder especially in diabetic patients, and possibly rejection and immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. As an example, as noted in a 2005 Cochrane review, routine intraoperative ureteric stenting is associated with an increased risk of UTI (RR of 1.45, 95% CI 1.04-2.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/4\">",
"     4",
"    </a>",
"    ]. With effective prophylaxis, however, the incidence of UTI has markedly decreased. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The typical microorganisms causing posttransplant UTI are the enteric gram negative bacilli and enterococci. In addition, Corynebacterium urealyticum (group D2) has been recognized as a potential pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This observation is clinically important because C. urealyticum is difficult to isolate and is not sensitive to conventional oral antibiotics. Complicated infections are more common among transplant recipients with prolonged anuria as dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of urinary tract infections, which is not different from those seen in patients who have not been transplanted, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=see_link\">",
"     \"Recurrent urinary tract infection in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TIMING OF UTI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morbidity associated with UTI appears to be related to the timing of the episode after transplantation. Infections occurring in the hospital are more serious, with bacteremia occurring in approximately 10 percent and graft infection in 90 percent of recipients. These infections may be associated with allograft dysfunction and may predispose to development of acute rejection.",
"   </p>",
"   <p>",
"    The clinical presentation of early posttransplantation UTI is variable. Some patients are asymptomatic whereas others present with fever, chills, and graft pain and tenderness. Allograft dysfunction can also occur in this setting.",
"   </p>",
"   <p>",
"    UTIs developing more than three to six months after transplantation, which are clinically indistinguishable from UTIs in the general population, have traditionally been considered more benign than early UTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Some evidence, however, suggests that late UTIs are not necessarily benign, being associated with an increased risk of mortality in one large retrospective cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/12\">",
"     12",
"    </a>",
"    ]. An increased incidence of UTI in men is also associated with benign prostatic hypertrophy, which may increase the risk of allograft loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased number of UTIs over time may also be associated with an enhanced risk of chronic allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The correlation between UTI and chronic rejection was examined in a study of 255 renal allograft recipients with and 351 patients without evidence of chronic rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/14\">",
"     14",
"    </a>",
"    ]. Beyond the third year after transplantation, patients with increased numbers of UTIs had a significantly enhanced risk of manifesting chronic rejection. They may also produce renal allograft scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/16\">",
"     16",
"    </a>",
"    ]. As a result, UTI should be aggressively diagnosed and treated in the transplant population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We routinely administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylactically, as this regimen has been shown to significantly reduce the incidence of UTI and resultant bacteremia in renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In one study, for example, 132 patients were randomly assigned to receive trimethoprim-sulfamethoxazole or placebo after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/18\">",
"     18",
"    </a>",
"    ]. Active therapy was associated with a marked reduction in the incidence of urinary tract infection after removal of the bladder catheter in the immediate postoperative period &mdash; nine versus 36 in the placebo group. The incidence of other bacterial infections was reduced as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=see_link&amp;anchor=H5#H5\">",
"     \"Differential diagnosis of infection following renal transplantation\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    should be adjusted according to renal function. Patients who are allergic to trimethoprim-sulfamethoxazole can be treated with any of the oral quinolones, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/1,19\">",
"     1,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We usually continue prophylactic therapy for six months to one year in patients with normal urinary tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20579/abstract/20\">",
"     20",
"    </a>",
"    ]. However, indefinite therapy is indicated in patients with a history of recurrent UTIs, anatomic urinary tract abnormalities, or a neurogenic bladder.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/1\">",
"      Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993; 44:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/2\">",
"      Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 1981; 70:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/3\">",
"      Lyerov&aacute; L, L&aacute;cha J, Skibov&aacute; J, et al. Urinary tract infection in patients with urological complications after renal transplantation with respect to long-term function and allograft survival. Ann Transplant 2001; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/4\">",
"      Wilson CH, Bhatti AA, Rix DA, Manas DM. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev 2005; :CD004925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/5\">",
"      de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/6\">",
"      Aguado JM, Salto E, Morales JM, et al. Corynebacterium urealyticum: a new and threatening pathogen for the renal transplant patient. Transplant Proc 1993; 25:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/7\">",
"      Domann E, Hong G, Imirzalioglu C, et al. Culture-independent identification of pathogenic bacteria and polymicrobial infections in the genitourinary tract of renal transplant recipients. J Clin Microbiol 2003; 41:5500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/8\">",
"      Wu YJ, Veale JL, Gritsch HA. Urological complications of renal transplant in patients with prolonged anuria. Transplantation 2008; 86:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/9\">",
"      Rao KV, Andersen RC. Long-term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 1988; 45:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/10\">",
"      Grekas D, Thanos V, Dioudis C, et al. Treatment of urinary tract infections with ciprofloxacin after renal transplantation. Int J Clin Pharmacol Ther Toxicol 1993; 31:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/11\">",
"      Dharnidharka VR, Agodoa LY, Abbott KC. Effects of urinary tract infection on outcomes after renal transplantation in children. Clin J Am Soc Nephrol 2007; 2:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/12\">",
"      Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004; 44:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/13\">",
"      Hurst FP, Neff RT, Falta EM, et al. Incidence, predictors, and associated outcomes of prostatism after kidney transplantation. Clin J Am Soc Nephrol 2009; 4:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/14\">",
"      M&uuml;ller V, Becker G, Delfs M, et al. Do urinary tract infections trigger chronic kidney transplant rejection in man? J Urol 1998; 159:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/15\">",
"      Schmaldienst S, Dittrich E, H&ouml;rl WH. Urinary tract infections after renal transplantation. Curr Opin Urol 2002; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/16\">",
"      Dupont PJ, Psimenou E, Lord R, et al. Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation 2007; 84:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/17\">",
"      Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis 1982; 4:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/18\">",
"      Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990; 89:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/19\">",
"      Hernandez Poblete G, Morales JM, Prieto C, et al. Usefulness of norfloxacine prophylaxis in late recurrent urinary tract infection after renal transplantation. Nephron 1990; 54:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20579/abstract/20\">",
"      Brown PD. Urinary Tract Infections in Renal Transplant Recipients. Curr Infect Dis Rep 2002; 4:525.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7298 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20579=[""].join("\n");
var outline_f20_6_20579=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TIMING OF UTI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40084?source=related_link\">",
"      Differential diagnosis of infection following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5514?source=related_link\">",
"      Recurrent urinary tract infection in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_6_20580="Clindamycin and benzoyl peroxide: Patient drug information";
var content_f20_6_20580=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clindamycin and benzoyl peroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36371?source=see_link\">",
"     see \"Clindamycin and benzoyl peroxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/11/28851?source=see_link\">",
"     see \"Clindamycin and benzoyl peroxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acanya&reg;;",
"     </li>",
"     <li>",
"      BenzaClin&reg;;",
"     </li>",
"     <li>",
"      Duac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BenzaClin&reg;;",
"     </li>",
"     <li>",
"      Clindoxyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clindamycin, benzoyl peroxide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: History of very loose stools called antibiotic-associated colitis, regional enteritis, or ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and hair from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use other pimple (acne) drugs with care. More skin irritation may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Throw away any part of Acanya&reg; not used after 10 weeks, Duac&reg; after 2 months, or BenzaClin&reg; after 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12229 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-85249D4AE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20580=[""].join("\n");
var outline_f20_6_20580=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152776\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854892\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017142\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017144\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017143\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017148\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017149\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017151\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017146\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017147\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017152\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017153\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36371?source=related_link\">",
"      Clindamycin and benzoyl peroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/11/28851?source=related_link\">",
"      Clindamycin and benzoyl peroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_6_20581="Treatment of chronic eosinophilic pneumonia";
var content_f20_6_20581=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic eosinophilic pneumonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Kevin K Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20581/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/6/20581/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic eosinophilic pneumonia (CEP) is a disorder characterized by an abnormal and marked accumulation of eosinophils in the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/1\">",
"     1",
"    </a>",
"    ]. CEP can often present as a fulminant illness with a constellation of symptoms including cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/2\">",
"     2",
"    </a>",
"    ]. Other characteristics of CEP include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma accompanies, precedes, or subsequently occurs, in over 50 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/3\">",
"       3",
"      </a>",
"      ]. A majority of patients are nonsmokers.",
"     </li>",
"     <li>",
"      The finding of bilateral peripheral or pleural-based opacities described as the \"photographic negative\" of pulmonary edema is virtually pathognomonic for the disease when seen on chest radiograph (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef86465 \" href=\"UTD.htm?21/20/21831\">",
"       image 1",
"      </a>",
"      )&nbsp;or high resolution computed tomography (",
"      <a class=\"graphic graphic_picture graphicRef86464 \" href=\"UTD.htm?4/19/4406\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Peripheral blood eosinophilia (&gt;6 percent), a very high sedimentation rate, C-reactive protein, iron deficiency anemia, and thrombocytosis are all common laboratory abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bronchoalveolar lavage (BAL) eosinophilia of greater than 25 percent is suggestive of CEP [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. These eosinophils appear to be activated, as evidenced by the presence of several different markers of activation, including increased release of eosinophil proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/7\">",
"       7",
"      </a>",
"      ]. Serial BAL examinations may be helpful in following the course of the disease but is rarely indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Histopathologic findings are characterized by interstitial and alveolar eosinophils and histiocytes, including multinucleated giant cells. Fibrosis is minimal, and bronchiolitis obliterans with organizing pneumonia is a common associated finding (",
"      <a class=\"graphic graphic_picture graphicRef77554 \" href=\"UTD.htm?6/58/7075\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this review, the treatment of chronic eosinophilic pneumonia and response to therapy are discussed. The evaluation and differential diagnosis of eosinophilic lung diseases, in general, and an approach to acute eosinophilic pneumonia are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=see_link\">",
"     \"Idiopathic acute eosinophilic pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 10 percent of patients with CEP spontaneously recover or improve. In addition, CEP occasionally leads to physiologically important, irreversible fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/8\">",
"     8",
"    </a>",
"    ], although death secondary to CEP is extremely unusual. As a result, therapy is indicated once alternative diagnoses of eosinophilic infiltration of the lung are excluded (particularly infectious causes).",
"   </p>",
"   <p>",
"    Patients with CEP are uniformly responsive to intravenous or oral glucocorticoids. Thus, an alternative diagnosis should be entertained if a patient is steroid-resistant.",
"   </p>",
"   <p>",
"    To date, no prospective studies evaluating a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    regimen have been performed in patients with CEP. Furthermore, such a trial is unlikely to be initiated, since most prednisone regimens are probably effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/2\">",
"     2",
"    </a>",
"    ]. There are no data currently available on therapies other than prednisone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate initial therapy for virtually all patients with CEP consists of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at a dose of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. We continue the initial dose for two weeks after the complete resolution of symptoms and plain chest radiographic abnormalities (usually four to six weeks). At that time, the dose can be decreased by 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and therapy continued for another eight weeks.",
"   </p>",
"   <p>",
"    Because relapses are common, treatment is maintained for at least three months, and usually for six to nine months. We recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    be reduced at 5 mg decrements every four weeks until complete cessation of therapy. An alternate&ndash;day regimen can be also be used for tapering when the prednisone dose is &le;15",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment of acute, rapidly progressive respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with rapidly progressive disease (especially if associated with respiratory failure), we have used three to five days of high dose intravenous corticosteroid therapy prior to initiating oral therapy. We administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    at an intravenous dose of 250 mg every six hours. Once the patient is stabilized, therapy is continued as outlined above for initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment of disease relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic or radiographic relapse is common (50 to 80 percent of cases) either after cessation of therapy or, less commonly, with tapering of the corticosteroid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Relapse can occur months to years following the initial presenting episode. Thus, corticosteroid therapy is occasionally continued indefinitely.",
"   </p>",
"   <p>",
"    In managing a relapse, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose should be increased to at least 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and maintained at that dose for one to two weeks beyond the control of symptoms. Thereafter, the dose is reduced to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and continued for another four weeks. If there is documented improvement, the dose is tapered by 5 mg every two to three weeks to the previous dose that maintained complete control of the disease. At this point (usually a dose &le;15",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    the clinician can do one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hold the dose at this level for an indefinite period of time",
"     </li>",
"     <li>",
"      Attempt to decrease the dose of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      by switching to alternate&ndash;day oral prednisone",
"     </li>",
"     <li>",
"      Add inhaled corticosteroids to the low&ndash;dose oral dose. The oral dose can then be slowly tapered (a decrease of 2.5 mg every three to four weeks) until the patient is treated only with inhaled glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inhaled glucocorticoids (1000 to 1500 mcg per 24 hours) appear to be effective in CEP. However, literature supporting its use is only in the form of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/10\">",
"     10",
"    </a>",
"    ]. The availability of inhaled formulations with higher dose per inhalation and greater potency may improve the efficacy of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ASSESSING THE RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical improvement is often dramatic and rapid in response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , with profound symptomatic relief occurring in many patients within 48 hours. A favorable response to corticosteroid therapy is typically defined by [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resolution of presenting symptoms, especially dyspnea, cough, and fever.",
"     </li>",
"     <li>",
"      Decline in peripheral eosinophilia.",
"     </li>",
"     <li>",
"      Marked reduction or clearing (in most cases) of roentgenographic abnormalities. Radiographic abnormalities may persist on CT scan for several weeks to months after clearing of the chest x&ndash;ray [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physiologic improvement as measured by FVC, TLC, DLCO, and resting and exercise gas exchange.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complete resolution of symptoms and radiographic abnormalities occurs within 14 days in most patients, and by one month in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/2\">",
"     2",
"    </a>",
"    ]. Symptoms and plain chest radiographs remain the most reliable and efficient guide to therapy. Although CT scanning is more sensitive for the detection of radiographic abnormalities, there is no information to suggest that following CT scans to assess disease activity is an improvement over plain chest radiographs.",
"   </p>",
"   <p>",
"    Peripheral eosinophil counts, erythrocyte sedimentation rate (ESR), and IgE levels have also been used to follow the clinical course during treatment. However, not all patients have abnormalities in these laboratory tests.",
"   </p>",
"   <p>",
"    Several reports have suggested that urinary eosinophil&ndash;derived neurotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/12\">",
"     12",
"    </a>",
"    ], circulating immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/13\">",
"     13",
"    </a>",
"    ], and BAL prostaglandin E2 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/14\">",
"     14",
"    </a>",
"    ] also correlate with disease activity. More data on these putative markers are necessary before using them to replace easily obtained clinical data for monitoring of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY AND LONG&ndash;TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of maintenance therapy is to control the disease with the smallest required dose of oral glucocorticoids in order to limit treatment-related side effects. Although the dose and length of therapy will vary for individual patients, an attempt to stop therapy is reasonable after six to nine months. However, one study found that three&ndash;fourths of patients required prolonged corticosteroid therapy, with a mean initial duration of 19 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, most patients require long&ndash;term treatment (one or more years) and a few require lifelong therapy; however, some patients can be weaned off therapy within six months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Importantly, relapse does",
"    <strong>",
"     not",
"    </strong>",
"    appear to indicate treatment failure, a worse prognosis, or greater morbidity. Patients with CEP continue to be steroid-responsive and to respond to corticosteroid doses at levels similar to those prior to the relapse. As a result, the outcome for most patients is excellent despite frequent recurrences and the occasional need for prolonged therapy. Fixed airflow obstruction can occur in some patients who recover from CEP, but the abnormalities are usually of borderline clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/16\">",
"     16",
"    </a>",
"    ]. In previously well-controlled patients who unexpectedly relapse or begin to require higher doses of oral glucocorticoids to maintain control, the development of another eosinophilic disorder (eg, Churg-Strauss Syndrome or hypereosinophilic syndrome) should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20581/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7592140\">",
"    <span class=\"h1\">",
"     PREVENTION OF GLUCOCORTICOID-RELATED SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic therapy with systemic glucocorticoids is associated with a number of side effects. Steps to monitor, prevent, and treat these side effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7592174\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic eosinophilic pneumonia (CEP) is characterized by the onset of dyspnea, cough, fever, and wheezing over three weeks to several months and the presence of a marked accumulation of eosinophils in the lung. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chest radiographic finding of bilateral peripheral or pleural-based opacities, described as the \"photographic negative\" of pulmonary edema, is virtually pathognomonic for CEP. Almost all patients will show complete resolution of the opacities with treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link&amp;anchor=H17#H17\">",
"       \"High resolution computed tomography of the lungs\", section on 'HRCT disease distribution'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A bronchoalveolar lavage (BAL) eosinophilia of greater than 25 percent provides further confirmation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy is indicated once alternative causes of eosinophilic infiltration of the lung are excluded (particularly infectious causes), as CEP rarely resolves spontaneously. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We usually initiate therapy with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of (0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). Subjective and radiographic improvement usually starts within 48 hours of initiating therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Initial treatment'",
"      </a>",
"      above.) For patients with rapidly progressive disease (especially if associated with respiratory failure), we typically initiate high dose intravenous glucocorticoid therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      60 to 125 mg every 6 hours) for three to five days prior to transitioning to oral therapy with prednisone. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment of acute, rapidly progressive respiratory failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We continue the initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for two weeks after the complete resolution of symptoms and plain chest radiographic abnormalities (usually four to six weeks into therapy). At that time, the dose can be decreased by one-half (0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and therapy continued for another eight weeks. Complete resolution of symptoms and radiographic abnormalities occurs within 14 days in most patients, and by one month in almost all patients. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Assessing the response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal duration of therapy is not known. After about 12 weeks, we usually taper",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      by 5 mg increments every four weeks as tolerated until complete cessation of therapy. Most patients require prolonged treatment (ie, more than 6 months) and 30 to 40 percent of cases will require prolonged therapy (ie, years). &nbsp;(See",
"      <a class=\"local\" href=\"#H7\">",
"       'Duration of therapy and long&ndash;term outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic therapy with systemic glucocorticoids is associated with a number of side effects. Steps to monitor, prevent, and treat these side effects are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/1\">",
"      Allen JN, Davis WB. Eosinophilic lung diseases. Am J Respir Crit Care Med 1994; 150:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/2\">",
"      Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore) 1988; 67:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/3\">",
"      Marchand E, Etienne-Mastroianni B, Chanez P, et al. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Eur Respir J 2003; 22:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/4\">",
"      Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol 1977; 128:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/5\">",
"      Matsuse H, Shimoda T, Fukushima C, et al. Diagnostic problems in chronic eosinophilic pneumonia. J Int Med Res 1997; 25:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/6\">",
"      Danel, C, Israel-Biet, D, Costabel, U, et al. The clinical role of BAL in rare pulmonary diseases. Eur Respir Rev 1991; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/7\">",
"      Janin A, Torpier G, Courtin P, et al. Segregation of eosinophil proteins in alveolar macrophage compartments in chronic eosinophilic pneumonia. Thorax 1993; 48:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/8\">",
"      Yoshida K, Shijubo N, Koba H, et al. Chronic eosinophilic pneumonia progressing to lung fibrosis. Eur Respir J 1994; 7:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/9\">",
"      Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d'Etudes et de Recherche sur les Maladies \"Orphelines\" Pulmonaires (GERM\"O\"P). Medicine (Baltimore) 1998; 77:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/10\">",
"      Minakuchi M, Niimi A, Matsumoto H, et al. Chronic eosinophilic pneumonia: treatment with inhaled corticosteroids. Respiration 2003; 70:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/11\">",
"      Ebara H, Ikezoe J, Johkoh T, et al. Chronic eosinophilic pneumonia: evolution of chest radiograms and CT features. J Comput Assist Tomogr 1994; 18:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/12\">",
"      Deviller P, Gruart V, Prin L, et al. Detection of an eosinophil derived neurotoxin in the urine of a patient with idiopathic chronic eosinophilic pneumonia. Clin Chim Acta 1991; 201:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/13\">",
"      Demedts M, De Man F. Circulating immune complexes in chronic eosinophilic pneumonia. Acta Clin Belg 1991; 46:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/14\">",
"      Ogushi F, Ozaki T, Kawano T, Yasuoka S. PGE2 and PGF2 alpha content in bronchoalveolar lavage fluid obtained from patients with eosinophilic pneumonia. Chest 1987; 91:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/15\">",
"      Naughton M, Fahy J, FitzGerald MX. Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest 1993; 103:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/16\">",
"      Durieu J, Wallaert B, Tonnel AB. Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia. Groupe d'Etude en Pathologie Interstitielle de la Soci&eacute;t&eacute; de Pathologie Thoracique du Nord. Eur Respir J 1997; 10:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20581/abstract/17\">",
"      Golstein MA, Steinfeld S. Chronic eosinophilic pneumonia followed by Churg-Strauss syndrome. Rev Rhum Engl Ed 1996; 63:624.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4360 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20581=[""].join("\n");
var outline_f20_6_20581=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7592174\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment of acute, rapidly progressive respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment of disease relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ASSESSING THE RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DURATION OF THERAPY AND LONG&ndash;TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7592140\">",
"      PREVENTION OF GLUCOCORTICOID-RELATED SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7592174\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4360\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4360|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/20/21831\" title=\"diagnostic image 1\">",
"      Chronic eosinophilic pneumonia CXR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4360|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/19/4406\" title=\"picture 1\">",
"      Chronic eosinophilic pneumonia HRCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/58/7075\" title=\"picture 2\">",
"      Chronic eosinophilic pneu Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_6_20582="Skin biopsy lichen sclerosis";
var content_f20_6_20582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Skin biopsy of lichen sclerosis et atrophicus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy in lichen sclerosis et atrophicus showing attenuation of the epidermis which is surmounted by a dense or hyperkeratotic scale (left panel). There is also homogenization of the dermis with hypovascularity (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20582=[""].join("\n");
var outline_f20_6_20582=null;
var title_f20_6_20583="Epidemiology and risk factors for head and neck cancer";
var content_f20_6_20583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and risk factors for head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20583/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20583/contributors\">",
"     Kerstin M Stenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20583/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20583/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/6/20583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head and neck cancer is common in several regions of the world. The primary risk factors associated with head and neck cancer include tobacco use, alcohol consumption, human papillomavirus (HPV) infection (for oropharyngeal cancer), and Epstein-Barr virus (EBV) infection (for nasopharyngeal cancer). The relative prevalence of these risk factors contributes to the variations in the observed distribution of head and neck cancer in different areas of the world.",
"   </p>",
"   <p>",
"    The chronic exposure of the upper aerodigestive tract to these and other risk factors is thought to produce field cancerization, a process in which patients with cancer or premalignant dysplastic lesions in the oropharyngeal mucosa are at significant risk for head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology of head and neck cancer and the risk factors for and pathogenesis of these tumors will be reviewed here. Issues related to pathology, diagnosis, staging, and therapy are considered separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, head and neck cancer accounts for more than 550,000 cases annually worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/1\">",
"     1",
"    </a>",
"    ]. Males are affected significantly more than females with a ratio ranging from 2:1 to 4:1. The incidence rate in males exceeds 20 per 100,000 in regions of France, Hong Kong, the Indian subcontinent, central and eastern Europe, Spain, Italy, Brazil and among African Americans in the Unites States. Mouth and tongue cancers are more common in the Indian subcontinent, nasopharyngeal cancer is more common in Hong Kong, and pharyngeal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laryngeal cancers are more common in other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, head and neck cancer accounts for 3 percent of malignancies, with an estimated 53,000 Americans developing head and neck cancer annually and 11,500 dying from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/3\">",
"     3",
"    </a>",
"    ]. The incidence in African American men during the years 1987 to 1991 was 24 per 100,000, approximately 50 percent higher than in white American men [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/4\">",
"     4",
"    </a>",
"    ]. The mortality associated with head and neck cancer in African Americans is also higher than in whites (median overall survival 21 versus 71 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/5\">",
"     5",
"    </a>",
"    ]. The poorer prognosis appears to be due in large part to poorer outcomes in patients with oropharyngeal cancer, which is much less common in black compared with white patients (4 versus 34 percent). In this study, HPV positivity was much less common in black patients (4 versus 34 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link&amp;anchor=H13764421#H13764421\">",
"     \"Human papillomavirus associated head and neck cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors most frequently associated with head and neck cancer include smoking, alcohol consumption, HPV infection (especially for oropharyngeal cancers), and EBV infection (for nasopharyngeal cancers in Asia) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of head and neck cancer, ranging from a 5- to 25-fold, in heavy cigarette smokers compared to nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. There appears to be a dose-response relationship as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study compared 605 patients with head and neck cancer to 756 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/8\">",
"       8",
"      </a>",
"      ]. The relative risk (RR) in current tobacco users was 6.5. The RR increased with the duration of smoking and gradually declined after smoking cessation with no excess risk at 20 years.",
"     </li>",
"     <li>",
"      In another case control study, patients who smoked more than one pack of cigarettes per day had a 13-fold increase in risk of head and neck cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/9\">",
"       9",
"      </a>",
"      ]. The age of starting smoking (below 18 years of age) and duration of smoking (over 35 years) were high risk factors. Cessation of smoking was associated with a significant decrease in relative risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epidemiologic studies suggest that cigar and pipe smoking are associated with an increased incidence of head and neck cancer (relative risk 2.0 to 2.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] and smokeless tobacco (both chewing tobacco and snuff) with an increased risk of cancer of the oral cavity and pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondhand smoke exposure may be a contributing factor. One report evaluated 59 patients with head and neck cancer who did not use tobacco and with rare exceptions did not abuse alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/16\">",
"     16",
"    </a>",
"    ]. These patients had a significantly higher risk of exposure to environmental tobacco smoke in both the workplace and home than a control population without cancer. This relationship primarily occurred in women and those with tongue cancer.",
"   </p>",
"   <p>",
"    Evidence regarding the association of marijuana use and the development of head and neck cancer is somewhat conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Reporting and selection bias as well as confounding by alcohol and tobacco use limit the ability of observational studies to exclude or confirm this relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol consumption independently increases the risk of cancer in the upper aerodigestive tract, although it is often difficult to separate the effects of smoking and alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/6,21-23\">",
"     6,21-23",
"    </a>",
"    ]. The relative risk of developing head and neck cancer due to alcohol appears to be dose dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/8,22,23\">",
"     8,22,23",
"    </a>",
"    ]. As an example, one study reported a five- to sixfold increased risk for head and neck cancer with alcohol intake greater than 50",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    versus less than 10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (one drink contains approximately 12 g of alcohol) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/23\">",
"     23",
"    </a>",
"    ]. Alcohol intake and tobacco smoking appear to have an interactive and multiplicative effect on the risk of developing head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/6-9,22,24\">",
"     6-9,22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be an interaction of genetic susceptibility and alcohol intake on the risk of developing head and neck cancer with genetic polymorphisms of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple types of viral infections have an established relationship with increased risk of head and neck cancer, including particularly Epstein-Barr virus (EBV), human papillomavirus (HPV), and human immunodeficiency virus (HIV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasopharyngeal carcinoma is a relatively rare malignancy in most populations but is one of the most common cancers in southern China. A large body of evidence supports the role of EBV as the primary etiologic agent in the pathogenesis of nasopharyngeal carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\", section on 'Epstein-Barr virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EBV is the primary etiologic agent for oral hairy leukoplakia. A possible relationship of oral hairy leukoplakia to squamous cell carcinoma is uncertain. While several investigators report finding EBV in oral squamous cell carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], others refute such a relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Malignancies and HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic and molecular evidence has established a causal role for HPV, primarily type 16, in patients with head and neck cancer, particularly those arising in the base of the tongue and the tonsils. HPV associated oropharyngeal cancers are typically seen in younger men who are nonusers of tobacco and alcohol. HPV associated head and neck cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1242771960\">",
"    <span class=\"h3\">",
"     Human immunodeficiency virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients infected with the human immunodeficiency virus (HIV) present with a variety of malignancies. There is an approximately two- to threefold increase in the incidence of squamous cell carcinoma of the head and neck in HIV-infected patients; other histologic types of cancer may also be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link&amp;anchor=H1560506375#H1560506375\">",
"     \"HIV infection and malignancy: Management considerations\", section on 'Head and neck cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus (HSV) is less strongly correlated with the development of oral carcinomas than EBV or HPV. Serologic studies have shown that patients with head and neck cancer have higher levels of IgM antibody to HSV type one than control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. HSV can transform cells in vitro to a malignant phenotype. This may be due to an HSV-encoded peptide that increases mutagenicity of infected cells. In one series of 31 young adults with head and neck cancer, antipeptide antibody levels were significantly higher in the patients than in control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1242772286\">",
"    <span class=\"h2\">",
"     Betel nut chewing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Betel nut chewing, which is widespread in certain regions of Asia, is an independent risk factor for the development of squamous cell head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The effects appear to be synergistic with tobacco and alcohol. Betel nut chewing is also implicated in the development of hepatocellular and esophageal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Occupational exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other occupational or environmental toxins have been studied for potential relationship with head and neck cancer. These include the dry cleaning agent perchloroethylene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/37\">",
"     37",
"    </a>",
"    ], asbestos, pesticides, man-made mineral vitreous fibers (MMMF), polycyclic aromatic hydrocarbons [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/38\">",
"     38",
"    </a>",
"    ], textile workers, wood workers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/39\">",
"     39",
"    </a>",
"    ], manufacturers of mustard gas, plastic and rubber products, naphthalene refiners, ethanol, sulfuric acid mist, leather and paint workers, automobile mechanics, construction workers (cement) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/40\">",
"     40",
"    </a>",
"    ], farmers, and metal workers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/41\">",
"     41",
"    </a>",
"    ]. Formaldehyde was classified as a carcinogen in 2004 because of its association with nasopharyngeal cancer and possibly cancers of the nasal cavity and paranasal sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior irradiation for either malignant or benign disease has been linked to salivary gland tumors, squamous cell cancers, and sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. Although this relationship is appears to be real, there is a long latency period [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and the overall risk is low [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some dietary factors may have a role in protecting individuals from head and neck cancer, while others may increase susceptibility for specific diseases. Several studies have shown a protective effect associated with increased consumption of fruits and vegetables [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In contrast, case control studies suggest that the risk of nasopharyngeal carcinoma is increased in frequent consumers of preserved meats that contain high levels of added nitrites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple genetic factors and pathways may contribute to an increase in risk of head and neck cancer, and these factors may interact with other known risk factors. Examples of these factors include metabolic polymorphisms that influence the exposure to the carcinogens in tobacco smoke, DNA repair gene polymorphisms, as well as variations in other pathways contributing to carcinogenesis.",
"   </p>",
"   <p>",
"    Patients with Fanconi anemia are at high risk for developing a malignancy, including squamous cell carcinoma of the head and neck, as well as myelodysplastic syndrome and acute myelocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Head and neck cancers in these patients tend to arise at an earlier age and in the absence of other risk factors (tobacco, alcohol). The management of patients with head and neck cancer arising in a patient with Fanconi anemia is complicated by the significant increase in susceptibility to complications of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors also may contribute to the development of head and neck cancer in selected patients. These include poor oral hygiene and periodontal disease, which has been linked with carcinoma of the oral cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/7,57,58\">",
"     7,57,58",
"    </a>",
"    ]. On the other hand, dental prostheses or poorly fitting dentures do not appear to be an independent risk factor for the development of oral carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20583/abstract/59-62\">",
"     59-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1407378194\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head and neck cancer is an important cause of cancer, accounting for more than 550,000 cases annually worldwide. Substantial geographic variations are heavily influenced by the key risk factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is 5- to 25-fold increased risk of head and neck cancer in heavy cigarette smokers compared to nonsmokers, and there is a significant increase in risk associated with pipe and cigar smoking as well. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol consumption significantly increases the risk of cancer in the upper aerodigestive tract, although it is often difficult to separate the effects of smoking and alcohol in epidemiologic studies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Alcohol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epstein Barr virus (EBV) is the primary etiologic agent in the pathogenesis of nasopharyngeal carcinoma. Although nasopharyngeal carcinoma is a relatively rare malignancy in most populations, it is one of the most common cancers in southern China. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\", section on 'Epstein-Barr virus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human papillomavirus (HPV) is implicated as a primary cause of oropharyngeal cancer in the United States and Europe. Head and neck cancers due to HPV have important clinical and prognostic differences compared with those typically associated with tobacco and alcohol use. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/1\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/2\">",
"      Sankaranarayanan R, Masuyer E, Swaminathan R, et al. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 1998; 18:4779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/3\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/4\">",
"      Walker B, Figgs LW, Zahm SH. Differences in cancer incidence, mortality, and survival between African Americans and whites. Environ Health Perspect 1995; 103 Suppl 8:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/5\">",
"      Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) 2009; 2:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/6\">",
"      Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48:3282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/7\">",
"      Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/8\">",
"      Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998; 82:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/9\">",
"      Andre K, Schraub S, Mercier M, Bontemps P. Role of alcohol and tobacco in the aetiology of head and neck cancer: a case-control study in the Doubs region of France. Eur J Cancer B Oral Oncol 1995; 31B:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/10\">",
"      Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 1999; 340:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/11\">",
"      Randi G, Scotti L, Bosetti C, et al. Pipe smoking and cancers of the upper digestive tract. Int J Cancer 2007; 121:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/12\">",
"      Proia NK, Paszkiewicz GM, Nasca MA, et al. Smoking and smokeless tobacco-associated human buccal cell mutations and their association with oral cancer--a review. Cancer Epidemiol Biomarkers Prev 2006; 15:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/13\">",
"      Sapkota A, Gajalakshmi V, Jetly DH, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. Int J Cancer 2007; 121:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/14\">",
"      Rosenquist K, Wennerberg J, Schildt EB, et al. Use of Swedish moist snuff, smoking and alcohol consumption in the aetiology of oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol 2005; 125:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/15\">",
"      Znaor A, Brennan P, Gajalakshmi V, et al. Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer 2003; 105:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/16\">",
"      Tan EH, Adelstein DJ, Droughton ML, et al. Squamous cell head and neck cancer in nonsmokers. Am J Clin Oncol 1997; 20:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/17\">",
"      Firth NA. Marijuana use and oral cancer: a review. Oral Oncol 1997; 33:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/18\">",
"      Zhang ZF, Morgenstern H, Spitz MR, et al. Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 1999; 8:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/19\">",
"      Aldington S, Harwood M, Cox B, et al. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg 2008; 138:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/20\">",
"      Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006; 15:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/21\">",
"      Kato I, Nomura AM. Alcohol in the aetiology of upper aerodigestive tract cancer. Eur J Cancer B Oral Oncol 1994; 30B:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/22\">",
"      Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007; 99:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/23\">",
"      De Stefani E, Boffetta P, Oreggia F, et al. Hard liquor drinking is associated with higher risk of cancer of the oral cavity and pharynx than wine drinking. A case-control study in Uruguay. Oral Oncol 1998; 34:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/24\">",
"      Murata M, Takayama K, Choi BC, Pak AW. A nested case-control study on alcohol drinking, tobacco smoking, and cancer. Cancer Detect Prev 1996; 20:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/25\">",
"      Druesne-Pecollo N, Tehard B, Mallet Y, et al. Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer. Lancet Oncol 2009; 10:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/26\">",
"      Cruz I, Van den Brule AJ, Steenbergen RD, et al. Prevalence of Epstein-Barr virus in oral squamous cell carcinomas, premalignant lesions and normal mucosa--a study using the polymerase chain reaction. Oral Oncol 1997; 33:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/27\">",
"      Kobayashi I, Shima K, Saito I, et al. Prevalence of Epstein-Barr virus in oral squamous cell carcinoma. J Pathol 1999; 189:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/28\">",
"      Cruz I, Van Den Brule AJ, Brink AA, et al. No direct role for Epstein-Barr virus in oral carcinogenesis: a study at the DNA, RNA and protein levels. Int J Cancer 2000; 86:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/29\">",
"      Goldenberg D, Benoit NE, Begum S, et al. Epstein-Barr virus in head and neck cancer assessed by quantitative polymerase chain reaction. Laryngoscope 2004; 114:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/30\">",
"      Shillitoe EJ, Greenspan D, Greenspan JS, Silverman S Jr. Five-year survival of patients with oral cancer and its association with antibody to herpes simplex virus. Cancer 1986; 58:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/31\">",
"      Larsson PA, Edstr&ouml;m S, Westin T, et al. Reactivity against herpes simplex virus in patients with head and neck cancer. Int J Cancer 1991; 49:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/32\">",
"      Das CM, Schantz SP, Shillitoe EJ. Antibody to a mutagenic peptide of herpes simplex virus in young adult patients with cancer of the head and neck. Oral Surg Oral Med Oral Pathol 1993; 75:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/33\">",
"      Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 2001; 37:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/34\">",
"      Lee KW, Kuo WR, Tsai SM, et al. Different impact from betel quid, alcohol and cigarette: risk factors for pharyngeal and laryngeal cancer. Int J Cancer 2005; 117:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/35\">",
"      Goldenberg D, Lee J, Koch WM, et al. Habitual risk factors for head and neck cancer. Otolaryngol Head Neck Surg 2004; 131:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/36\">",
"      Thomas SJ, Bain CJ, Battistutta D, et al. Betel quid not containing tobacco and oral cancer: a report on a case-control study in Papua New Guinea and a meta-analysis of current evidence. Int J Cancer 2007; 120:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/37\">",
"      Vaughan TL, Stewart PA, Davis S, Thomas DB. Work in dry cleaning and the incidence of cancer of the oral cavity, larynx, and oesophagus. Occup Environ Med 1997; 54:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/38\">",
"      Becher H, Ramroth H, Ahrens W, et al. Occupation, exposure to polycyclic aromatic hydrocarbons and laryngeal cancer risk. Int J Cancer 2005; 116:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/39\">",
"      Gordon I, Boffetta P, Demers PA. A case study comparing a meta-analysis and a pooled analysis of studies of sinonasal cancer among wood workers. Epidemiology 1998; 9:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/40\">",
"      Dietz A, Ramroth H, Urban T, et al. Exposure to cement dust, related occupational groups and laryngeal cancer risk: results of a population based case-control study. Int J Cancer 2004; 108:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/41\">",
"      Maier H, De Vries N, Snow GB. Occupational factors in the aetiology of head and neck cancer. Clin Otolaryngol Allied Sci 1991; 16:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/42\">",
"      Vaughan TL, Strader C, Davis S, Daling JR. Formaldehyde and cancers of the pharynx, sinus and nasal cavity: I. Occupational exposures. Int J Cancer 1986; 38:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/43\">",
"      Hauptmann M, Lubin JH, Stewart PA, et al. Mortality from solid cancers among workers in formaldehyde industries. Am J Epidemiol 2004; 159:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/44\">",
"      Vaughan TL, Stewart PA, Teschke K, et al. Occupational exposure to formaldehyde and wood dust and nasopharyngeal carcinoma. Occup Environ Med 2000; 57:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/45\">",
"      Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998; 149:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/46\">",
"      Miyahara H, Sato T, Yoshino K. Radiation-induced cancers of the head and neck region. Acta Otolaryngol Suppl 1998; 533:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/47\">",
"      van der Laan BF, Baris G, Gregor RT, et al. Radiation-induced tumours of the head and neck. J Laryngol Otol 1995; 109:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/48\">",
"      Sale KA, Wallace DI, Girod DA, Tsue TT. Radiation-induced malignancy of the head and neck. Otolaryngol Head Neck Surg 2004; 131:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/49\">",
"      Whatley WS, Thompson JW, Rao B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg 2006; 134:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/50\">",
"      Kang HK. Feasibility of an epidemiologic study of submariners who received radium irradiation treatment. Otolaryngol Head Neck Surg 1996; 115:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/51\">",
"      Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and head and neck cancer risk in a large United States prospective cohort study. Int J Cancer 2008; 122:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/52\">",
"      Boeing H, Dietrich T, Hoffmann K, et al. Intake of fruits and vegetables and risk of cancer of the upper aero-digestive tract: the prospective EPIC-study. Cancer Causes Control 2006; 17:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/53\">",
"      Farrow DC, Vaughan TL, Berwick M, et al. Diet and nasopharyngeal cancer in a low-risk population. Int J Cancer 1998; 78:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/54\">",
"      Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/55\">",
"      Rosenberg PS, Alter BP, Ebell W. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008; 93:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/56\">",
"      Birkeland AC, Auerbach AD, Sanborn E, et al. Postoperative clinical radiosensitivity in patients with fanconi anemia and head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2011; 137:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/57\">",
"      Velly AM, Franco EL, Schlecht N, et al. Relationship between dental factors and risk of upper aerodigestive tract cancer. Oral Oncol 1998; 34:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/58\">",
"      Tezal M, Sullivan MA, Reid ME, et al. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg 2007; 133:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/59\">",
"      Campbell BH, Mark DH, Soneson EA, et al. The role of dental prostheses in alveolar ridge squamous carcinomas. Arch Otolaryngol Head Neck Surg 1997; 123:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/60\">",
"      Morse DE, Katz RV, Pendrys DG, et al. Mouthwash use and dentures in relation to oral epithelial dysplasia. Oral Oncol 1997; 33:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/61\">",
"      Lockhart PB, Norris CM Jr, Pulliam C. Dental factors in the genesis of squamous cell carcinoma of the oral cavity. Oral Oncol 1998; 34:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20583/abstract/62\">",
"      Schildt EB, Eriksson M, Hardell L, Magnuson A. Oral infections and dental factors in relation to oral cancer: a Swedish case--control study. Eur J Cancer Prev 1998; 7:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3390 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20583=[""].join("\n");
var outline_f20_6_20583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1407378194\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1242771960\">",
"      - Human immunodeficiency virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1242772286\">",
"      Betel nut chewing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Occupational exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1407378194\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=related_link\">",
"      Head and neck squamous cell carcinogenesis: Molecular and genetic alterations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_6_20584="Electron microscopy in minimal change disease";
var content_f20_6_20584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron microscopy in minimal change disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph in minimal change disease showing a normal glomerular basement membrane (GBM), no immune deposits, and the characteristic widespread fusion of the epithelial cell foot processes (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20584=[""].join("\n");
var outline_f20_6_20584=null;
var title_f20_6_20585="Telaprevir: Drug information";
var content_f20_6_20585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Telaprevir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=see_link\">",
"    see \"Telaprevir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F16327820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12851805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Incivek&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13374970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Incivek&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F12851241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent;",
"     </li>",
"     <li>",
"      Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F12858873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of chronic hepatitis C (CHC):",
"     </b>",
"     Oral: 750 mg 3 times/day (in combination with peginterferon alfa and ribavirin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Treatment-naive or prior relapse patients:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Relapse includes patients with an undetectable HCV-RNA upon completion of treatment (non-telaprevir based regimen) but with detectable HCV-RNA during the follow up period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-12: Triple therapy: Telaprevir 750 mg 3 times/day in combination with peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 13-23 (based on HCV-RNA results at weeks 4 and 12):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     (level less than ~10-15 units/mL) at both weeks 4 and 12 (eRVR): Dual therapy: Peginterferon alfa with concomitant ribavirin only (through week 24)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level greater than ~10-15 units/mL but &le;1000 units/mL) at week 4 and/or week 12: Dual therapy: Peginterferon alfa and ribavirin only (through week 48 discussed below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level &gt;1000 units/mL) at week 4 or week 12 (treatment futility): Discontinue telaprevir, peginterferon alfa and ribavirin at week 12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks &ge;24 (based on HCV-RNA results at week 24):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level greater than ~10-15 units/mL but &le;1000 units/mL) at week 4 and/or week 12: Peginterferon alfa with concomitant ribavirin only (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level greater than ~10-15 units/mL) at week 24 (treatment futility): Discontinue peginterferon alfa and concomitant ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Treatment-naive patients with cirrhosis, compensated:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-12: Triple therapy: Telaprevir 750 mg 3 times/day in combination with peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 13-24 (based on HCV-RNA results at weeks 4 and 12):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     at both weeks 4 and 12 (eRVR): Dual therapy: Peginterferon alfa and ribavirin only (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level greater than ~10-15 units/mL but &le;1000 units/mL) at week 4 and/or week 12: Dual therapy: Peginterferon alfa and ribavirin only (through week 48 discussed below)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level &gt;1000 units/mL) at week 4 or week 12 (treatment futility): Discontinue telaprevir, peginterferon alfa and ribavirin at week 12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks &ge;24 (based on HCV-RNA results at week 24):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     at week 24: Peginterferon alfa with concomitant ribavirin only (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level greater than ~10-15 units/mL) at week 24 (treatment futility): Discontinue peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Previously-treated patients (partial response or null responders):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Previously treated does not include prior treatment with telaprevir. Partial response includes patients with a &gt;2-log",
"     <sub>",
"      10",
"     </sub>",
"     HCV-RNA decrease by week 12 but a nonsustained virologic response thereafter. Null response includes patients with a &lt;2-log",
"     <sub>",
"      10",
"     </sub>",
"     HCV-RNA decrease at week 12.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 1-12: Triple therapy: Telaprevir 750 mg 3 times/day with peginterferon alfa and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 13-48 (based on HCV-RNA results at weeks 4 and 12):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      undetectable",
"     </b>",
"     (level less than ~10-15 units/mL) or detectable (level &le;1000 units/mL) at both weeks 4 and 12: Dual therapy: Peginterferon alfa and ribavirin only (through week 48)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level &gt;1000 units/mL) at week 4 or week 12: Discontinue telaprevir, peginterferon alfa, and ribavirin at week 12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     HCV-RNA",
"     <b>",
"      detectable",
"     </b>",
"     (level greater than ~10-15 units/mL) at week 24: Discontinue peginterferon alfa and concomitant ribavirin",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F12858874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F12858875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: No dosage adjustment necessary. Not studied in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute or in hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa and Ribavirin: Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F12858876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Telaprevir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild (Child-Pugh class A) impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate or severe (Child-Pugh class B-C) impairment: Use is not recommended; has not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Peginterferon Alfa and Ribavirin: Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12851292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Incivek&trade;: 375 mg [28-day pack]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12858848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12858847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM256383.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM256383.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F12858878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a meal (not low fat). Doses should be taken approximately every 7-9 hours. Administer concurrently with peginterferon alfa and ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12851242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of genotype 1 chronic hepatitis C (in combination with peginterferon alfa and ribavirin) in adult patients with compensated liver disease (including cirrhosis) who are treatment naive or who have received previous interferon-based treatment, including null or partial responders, and treatment relapsers.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12858856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (56%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (56%), pruritus (47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine and Metabolic: Hyperuricemia (&lt;12.1 mg/dL: 66%; &ge;12.1 mg/dL: 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (39%), diarrhea (26%), vomiting (13%), hemorrhoids (12%), anorectal discomfort (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (36%), lymphopenia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (&lt;2.6 x ULN: 37%; &ge;2.6 x ULN: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abnormal taste (10%), anal pruritus (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12858853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination treatment with ribavirin: Pregnancy; male partners of pregnant women",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Coadministration with CYP 3A4 highly dependent substrates (alfuzosin, cisapride, ergot derivatives, lovastatin, midazolam [oral], pimozide, sildenafil/tadalafil [when used for treatment of pulmonary arterial hypertension], simvastatin, triazolam), or strong CYP 3A4 inducers (rifampin, St John&rsquo;s wort)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to telaprevir or any component of the formulation; coadministration with amiodarone, atorvastatin, eletriptan, flecainide, propafenone, quinidine, terfenadine, vardenafil",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Also refer to Peginterferon Alfa and Ribavirin monographs for individual product contraindications.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12858958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Has been reported with peginterferon alfa and ribavirin; addition of telaprevir is associated with a further reduction in hemoglobin. Low hemoglobin levels were measured during the first 4 weeks of treatment, and the lowest at the end of telaprevir treatment (week 12). Dose modifications of ribavirin were needed more often in patients also taking telaprevir. Assess complete blood count (CBC) pretreatment, at weeks 2, 4, 8, and 12, and when clinically indicated. May require ribavirin dose reduction, interruption or discontinuation of treatment; if ribavirin dose reductions are inadequate, may consider discontinuing telaprevir. Do not reduce telaprevir dose. If ribavirin is discontinued, telaprevir must also be discontinued. Do not restart telaprevir if ribavirin therapy is reinitiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Serious skin reactions (some fatal) including Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), have been reported with telaprevir combination therapy. Fatal cases have been reported in patients with progressive rash and systemic symptoms who received ongoing therapy after diagnoses of serious skin reactions. Discontinue telaprevir, peginterferon alfa, and ribavirin immediately for serious skin reactions (including rash with systemic symptoms or a progressive severe rash).",
"     </b>",
"     Rash has been typically observed within first 4 weeks of therapy initiation but may occur at any time. Severe rashes (other than DRESS, SJS) are generalized, bullous, vesicular or ulcerative; may also have an eczematous appearance. Discontinue telaprevir (may continue peginterferon alfa and ribavirin) for severe rash or for mild-to-moderate rash that progresses; if no improvement in rash within 1 week of stopping telaprevir, interruption or discontinuation of peginterferon alfa and/or ribavirin should be considered (or sooner if clinically indicated). May use oral antihistamines/topical corticosteroids for rash treatment; do not use systemic corticosteroids. Do not restart telaprevir if discontinued due to any skin reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Not recommended in moderate or severe hepatic impairment (Child-Pugh class B or C) or decompensated hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustments, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy and/or women of childbearing potential: Combination therapy with ribavirin may cause birth defects; avoid pregnancy in females and female partners of male patients. Combination therapy with ribavirin is contraindicated in pregnancy. Hormonal contraceptives may not be effective in patients taking telaprevir or for 2 weeks after discontinuing therapy. Use 2 effective nonhormonal forms of contraception during treatment and for 2 weeks after telaprevir completion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Should only be used in combination with peginterferon alfa and ribavirin (do not use as monotherapy). Safety and efficacy have not been established in patients who have received organ transplants, have decompensated cirrhosis, or have been coinfected with hepatitis B or HIV, or who have failed to respond to other NS3/4A inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong), P-glycoprotein, SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12881545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Telaprevir may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Telaprevir may increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Telaprevir may enhance the adverse/toxic effect of Amiodarone. Telaprevir may increase the serum concentration of Amiodarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Telaprevir may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Telaprevir may enhance the adverse/toxic effect of Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): Telaprevir may increase the serum concentration of Budesonide (Nasal).  Management: Concurrent use of telaprevir with inhaled budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): Telaprevir may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Concurrent use of telaprevir with budesonide is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Telaprevir may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Clarithromycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Telaprevir may increase the serum concentration of Colchicine.  Management: Colchicine should not be used with telaprevir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with telaprevir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Telaprevir may decrease the serum concentration of Contraceptives (Estrogens).  Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Telaprevir may decrease the serum concentration of Contraceptives (Progestins).  Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Telaprevir may increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Telaprevir may increase the serum concentration of CycloSPORINE (Systemic).  Management: Significant cyclosporine dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both cyclosporine concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Telaprevir may increase the serum concentration of Digoxin.  Management: Use the lowest possible digoxin dose when starting therapy in a patient who is being treated with telaprevir, and monitor clinical response and serum concentrations closely for further dosing adjustments.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Telaprevir may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Telaprevir may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Telaprevir may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Telaprevir may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Erythromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Escitalopram: Telaprevir may decrease the serum concentration of Escitalopram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Telaprevir may enhance the adverse/toxic effect of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): Telaprevir may increase the serum concentration of Fluticasone (Nasal).  Management: Concurrent use of telaprevir with inhaled fluticasone is not recommended, unless the risk for excessive systemic corticosteroid effects is outweighed by the potential benefits.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: Telaprevir may increase the serum concentration of Fluvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Fosphenytoin. Telaprevir may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Itraconazole. Management: Doses of itraconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Ketoconazole (Systemic). Management: Doses of ketoconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Telaprevir may enhance the adverse/toxic effect of Lidocaine (Systemic). Telaprevir may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Telaprevir may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Telaprevir may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Telaprevir may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Telaprevir may increase the serum concentration of Midazolam.  Management: Use of oral midazolam with telaprevir is contraindicated.  IV midazolam use may pose a lower risk, but dose reductions should be considered and patients should be monitored closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of PHENobarbital. Telaprevir may increase the serum concentration of PHENobarbital.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Phenytoin. Telaprevir may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Telaprevir may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Telaprevir may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Telaprevir may increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Telaprevir may enhance the adverse/toxic effect of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Telaprevir may enhance the adverse/toxic effect of QuiNIDine. Telaprevir may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Telaprevir may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: May decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Telaprevir may increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: Telaprevir may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Telaprevir may increase the serum concentration of Sildenafil.  Management: Concurrent use of sildenafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg per 48 hours, with close monitoring for sildenafil toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Telaprevir may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Telaprevir may increase the serum concentration of Sirolimus.  Management: Significant sirolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both sirolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Telaprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Telaprevir may increase the serum concentration of Tacrolimus (Systemic).  Management: Significant tacrolimus dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both tacrolimus concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Telaprevir may increase the serum concentration of Tadalafil.  Management: Concurrent use of tadalafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Tadalafil for erectile dysfunction should be limited to 10 mg per 72 hours, with close monitoring for tadalafil toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telithromycin: Telaprevir may increase the serum concentration of Telithromycin. Telithromycin may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Telaprevir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Telaprevir may increase the serum concentration of TraZODone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Telaprevir may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Telaprevir may increase the serum concentration of Vardenafil.  Management: In patients receiving telaprevir, vardenafil dosing should be limited to 2.5 mg per 72-hour period with close monitoring for signs/symptoms of vardenafil toxicity (including hypotension, visual changes, syncope, and priapism).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Telaprevir may decrease the serum concentration of Voriconazole. Telaprevir may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Telaprevir.  Management: Concurrent use of telaprevir and voriconazole should be avoided due to the uncertain impact on drug concentrations and effects unless the benefit/risk ratio justifies its use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Telaprevir may decrease the serum concentration of Warfarin. Telaprevir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Telaprevir may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12858849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B / X (in combination with ribavirin)  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12858850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in telaprevir animal developmental studies; however, telaprevir must not be used as monotherapy (must be used in combination with peginterferon alfa and ribavirin). Significant ribavirin teratogenic effects have been observed in all animal studies at ~0.01 times the maximum recommended daily human dose. Use of ribavirin is contraindicated in pregnancy. In addition, animal studies with interferons have demonstrated abortifacient effects. Negative pregnancy test is required before initiation and monthly thereafter. Hormonal contraceptive measures may not be effective in patients taking telaprevir or for 2 weeks after discontinuing therapy. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective nonhormonal forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure. If pregnancy occurs during use or within 6 months after treatment, report to the ribavirin pregnancy registry (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12858851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12858852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if telaprevir or ribavirin are excreted into breast milk. The manufacturer recommends that breast-feeding be discontinued prior to the initiation of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F12858877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with a meal (not low fat).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Incivek Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     375 mg (168): $22110.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12858880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CBC with differential, serum electrolytes, TSH, bilirubin, liver enzymes, and uric acid at baseline and weeks 2, 4, 8 and 12, then periodically (and when clinically indicated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum HCV-RNA at baseline, weeks 4, 8, 12 and 24, end of treatment, during treatment follow up, and when clinically indicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pretreatment and monthly pregnancy test up to 6 months following discontinuation of therapy for women of childbearing age",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F12858862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Treatment futility: HCV-RNA &ge;1000 units/mL at treatment week 4 or 12 or confirmed, detectable HCV-RNA at treatment week 24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rapid virologic response (RVR): Absence of detectable HCV-RNA after 4 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended rapid virologic response (eRVR): Absence of detectable HCV-RNA after 4 and 12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Early virologic response (EVR): Absence of detectable HCV-RNA after 12 weeks of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sustained virologic response (SVR): Absence of HCV-RNA in the serum 32-78 weeks after completion of a 24 week treatment course or 56-78 weeks after a 48 week treatment course.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Incivo (CH, CZ, DK, EE, FR, GB, NO, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12858860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds reversibly to nonstructural protein 3 (NS 3) serine protease and inhibits replication of the hepatitis C virus. Considered a direct-acting antiviral treatment for HCV, also called a specifically targeted antiviral therapy for HCV (STAT-C).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12858863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Food (not low fat) enhances absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~252 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 59% to 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic to less active (30x) and inactive metabolites. Some oxidative CYP3A4 metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Plasma: Adults: ~4-5 hours (single dose); steady state: ~9-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (82%); urine (1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forestier N, Reesink HW, Weegink CJ, et al, &ldquo;Antiviral Activity of Telaprevir (VX-950) and Peginterferon Alfa-2a in Patients With Hepatitis C,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2007, 46:640-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, &ldquo;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/6/20585/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hezode C, Forestier N, Dusheiko G, et al, &ldquo;Telaprevir and Peginterferon With or Without Ribavirin for Chronic HCV Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360:1839-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoofnagle JH and Seeff LB,&rdquo;Peginterferon and Ribavirin for Chronic Hepatitis C,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(23):2444-51.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lauer GM and Walker BD, &ldquo;Hepatitis C Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(1):41-52.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McHutchison JG, Manns MP, Muir AJ, et al, &ldquo;Telaprevir for Previously Treated Chronic HCV Infection&rdquo;,",
"      <i>",
"       N Engl J Med",
"      </i>",
"      2010, 362: 1292-303.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McHutchison JG, Everson GT, Gordon SC, et al, &ldquo;Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection&rdquo;,",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360:1827-38.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith LS, Nelson M, Naik S, Woten J, &ldquo;Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C&rdquo;,",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2011, 45:639-48.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16495 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20585=[""].join("\n");
var outline_f20_6_20585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16327820\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851805\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374970\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851241\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858873\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858874\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858875\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858876\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858848\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858847\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858878\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851242\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858856\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858853\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858958\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300107\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12881545\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858849\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858850\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858851\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858852\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858877\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322902\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858880\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858862\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992822\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858860\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12858863\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16495|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/19/24885?source=related_link\">",
"      Telaprevir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_6_20586="Clinical and laboratory aspects of platelet transfusion therapy";
var content_f20_6_20586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical and laboratory aspects of platelet transfusion therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Shan Yuan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Dennis Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/6/20586/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/6/20586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H382870434\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemostasis depends on an adequate number of functional platelets, together with an intact coagulation (clotting factor) system. This topic covers the logistics of platelet use and the indications for platelet transfusion in adults. The approach to the bleeding patient, refractoriness to platelet transfusion, and platelet transfusion in neonates are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"       \"Approach to the adult patient with a bleeding diathesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link\">",
"       \"Refractoriness to platelet transfusion therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H45#H45\">",
"       \"Neonatal thrombocytopenia\", section on 'Platelet transfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558382031\">",
"    <span class=\"h1\">",
"     PLATELET COLLECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two ways that platelets can be collected: by isolation from a unit of donated blood, or by apheresis from a donor in the blood bank.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pooled platelets",
"      </strong>",
"      &mdash; A single unit of platelets can be isolated from every unit of donated blood, by centrifuging the blood within the closed collection system to separate the platelets from the red blood cells (RBC). The number of platelets per unit varies according to the platelet count of the donor; a yield of 7 x 10",
"      <sup>",
"       10",
"      </sup>",
"      platelets is typical [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/1\">",
"       1",
"      </a>",
"      ]. Since this number is inadequate to raise the platelet count in an adult recipient, four to six units are pooled to allow transfusion of 3 to 4 x 10",
"      <sup>",
"       11",
"      </sup>",
"      platelets per transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/2\">",
"       2",
"      </a>",
"      ]. These are called whole blood-derived or random donor pooled platelets.",
"      <br/>",
"      <br/>",
"      Advantages of pooled platelets include lower cost and ease of collection and processing (a separate donation procedure and pheresis equipment are not required). The major disadvantage is recipient exposure to multiple donors in a single transfusion and logistic issues related to bacterial testing.",
"     </li>",
"     <li>",
"      <strong>",
"       Apheresis (single donor) platelets",
"      </strong>",
"      &mdash; Platelets can also be collected from volunteer donors in the blood bank, in a one- to two-hour pheresis procedure. Platelets and some white blood cells are removed, and red blood cells and plasma are returned to the donor. A typical apheresis platelet unit provides the equivalent of six or more units of platelets from whole blood (ie, 3 to 6 x 10",
"      <sup>",
"       11",
"      </sup>",
"      platelets) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/2\">",
"       2",
"      </a>",
"      ]. In larger donors with high platelet counts, up to three units can be collected in one session. These are called apheresis or single donor platelets.",
"      <br/>",
"      <br/>",
"      Advantages of single donor platelets are exposure of the recipient to a single donor rather than multiple donors, and the ability to match donor and recipient characteristics such as HLA type, cytomegalovirus (CMV) status, and blood type for certain recipients. (See",
"      <a class=\"local\" href=\"#H382870465\">",
"       'Ordering platelets'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Issues related to the effects of platelet pheresis on the donor are covered elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H17#H17\">",
"       \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Apheresis platelet donors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both pooled and apheresis platelets are contaminated with some white blood cells (WBC) that were collected along with the platelets. These WBC can cause febrile non-hemolytic transfusion reactions (FNHTR), alloimmunization, and transfusion-associated graft-versus-host disease (ta-GVHD) in some patients.",
"   </p>",
"   <p>",
"    Platelets are also contaminated with plasma, which can be implicated in adverse reactions including transfusion-related acute lung injury (TRALI) and anaphylaxis. (See",
"    <a class=\"local\" href=\"#H382870592\">",
"     'Complications of platelet transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several strategies are used to prevent the complications associated with WBC and plasma contamination of platelets. (See",
"    <a class=\"local\" href=\"#H382870465\">",
"     'Ordering platelets'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Platelets are also contaminated with a small number of red blood cells that express Rh antigens on their surface, unlike platelets that do not. The low level of red cell contamination in apheresis platelets negates the issue of Rh alloimmunization not clinically relevant in most patients. However, blood banks avoid giving platelets from Rh",
"    <sup>",
"     +",
"    </sup>",
"    donors to Rh",
"    <sup>",
"     -",
"    </sup>",
"    female patients because of the potential risk of Rh alloimmunization and subsequent hemolytic disease of the newborn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870457\">",
"    <span class=\"h1\">",
"     PLATELET STORAGE AND PATHOGEN REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are stored at room temperature, because cold induces clustering of von Willebrand factor receptors on the platelet surface and morphological changes of the platelets, leading to enhanced clearance by hepatic macrophages and reduced platelet survival in the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All cells are more metabolically active at room temperature, so platelets are stored in bags that allow oxygen and carbon dioxide gas exchange. Citrate is included to prevent clotting and maintain proper pH, and dextrose is added as an energy source [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A disadvantage of room temperature storage is the increased growth of contaminating bacteria compared with blood products stored in the refrigerator or freezer. (See",
"    <a class=\"local\" href=\"#H382870592\">",
"     'Complications of platelet transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Strategies for reducing exposure to contaminating pathogens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donor screening for bloodborne pathogens (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H8#H8\">",
"       \"Laboratory testing of donated blood\", section on 'Infectious disease screening'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=see_link&amp;anchor=H3#H3\">",
"       \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\", section on 'Specific donor screening procedures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Proper skin sterilization techniques during collection, and discarding the first 15 to 30 mL of blood collected, which is most likely to be contaminated by skin bacteria",
"     </li>",
"     <li>",
"      Performing tests to screen for bacterial contamination, such as automated culture-based assays, and rapid point-of-issue tests (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link&amp;anchor=H1969743#H1969743\">",
"       \"Transfusion transmitted bacterial infection\", section on 'Detection of contamination'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Using blood products that have been subjected to pathogen inactivation or reduction treatment (not available in the United States) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathogen inactivation of blood products\", section on 'Pathogen inactivation of platelets'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link&amp;anchor=H14#H14\">",
"       \"Preparation of blood components\", section on 'Pathogen reduction'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The shelf life of platelets stored at room temperature is five days because of the bacterial contamination risk that increases in relationship to the storage duration. This short shelf life contributes to the greater sensitivity of platelet inventory to shortages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558384432\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PLATELET TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets can be transfused therapeutically (ie, to treat active bleeding or in preparation for an invasive procedure that would cause bleeding), or prophylactically, to prevent spontaneous bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558395184\">",
"    <span class=\"h2\">",
"     Actively bleeding patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actively bleeding patients with thrombocytopenia should be transfused with platelets immediately to keep platelet counts above",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    in most bleeding situations, and above",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    if there is disseminated intravascular coagulation or central nervous system bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H13#H13\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Treatment'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Other factors contributing to bleeding should also be addressed. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Surgical or anatomic defect",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Infection or inflammation",
"     </li>",
"     <li>",
"      Coagulopathy",
"     </li>",
"     <li>",
"      Acquired or inherited platelet function defect",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose and frequency of platelet transfusions will depend on the platelet count and the severity of bleeding. (See",
"    <a class=\"local\" href=\"#H382870473\">",
"     'Dose'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558384448\">",
"    <span class=\"h2\">",
"     Preparation for an invasive procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are transfused in preparation for an invasive procedure if the thrombocytopenia is severe and the risks of bleeding are deemed high. Most of the data used to determine bleeding risk come from retrospective studies of patients who are afebrile and have thrombocytopenia but not coagulopathy. Typical platelet count thresholds that are used for some common procedures are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neurosurgery or ocular surgery &ndash;",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Most other major surgery &ndash;",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Endoscopic procedures &ndash;",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      for therapeutic procedures;",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"      for low risk diagnostic procedures (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central line placement &ndash;",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lumbar puncture &ndash; 10,000 to",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"      in patients with hematologic malignancies and greater than 40,000 to 50,000 in patients without hematologic malignancies, but lower in patients with immune thrombocytopenic purpura [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/8-10\">",
"       8-10",
"      </a>",
"      ] &nbsp;",
"     </li>",
"     <li>",
"      Epidural anesthesia &ndash;",
"      <span class=\"nowrap\">",
"       80,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Bone marrow",
"      <span class=\"nowrap\">",
"       aspiration/biopsy",
"      </span>",
"      &ndash;",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H607102529\">",
"    <span class=\"h2\">",
"     Prevention of spontaneous bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic transfusion is used to prevent spontaneous bleeding in patients at high risk of bleeding. It is therefore helpful to have an estimate of the patient&rsquo;s risk of bleeding. The threshold for prophylactic transfusion varies depending on the patient and on the clinical scenario. (See",
"    <a class=\"local\" href=\"#H558395341\">",
"     'Specific clinical scenarios'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4185989\">",
"    <span class=\"h3\">",
"     Predicting spontaneous bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no ideal tests for predicting who will bleed spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/11\">",
"     11",
"    </a>",
"    ]. Studies of patients with thrombocytopenia suggest that patients can bleed even with platelet counts greater than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/12\">",
"     12",
"    </a>",
"    ]. However, bleeding is much more likely at platelet counts less than",
"    <span class=\"nowrap\">",
"     5000/microL.",
"    </span>",
"    Among individuals with platelet counts between",
"    <span class=\"nowrap\">",
"     5000/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    clinical findings can be helpful in decision-making regarding platelet transfusion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The platelet count at which a patient bled previously can be a good predictor of future bleeding.",
"     </li>",
"     <li>",
"      Petechial bleeding and ecchymoses are generally not thought to be predictive of serious bleeding, whereas mucosal bleeding and epistaxis (so-called &ldquo;wet&rdquo; bleeding) are thought to be predictive.",
"     </li>",
"     <li>",
"      Coexisting inflammation, infection, and fever also increase bleeding risk.",
"     </li>",
"     <li>",
"      The underlying condition responsible for a patient&rsquo;s thrombocytopenia also may help in estimating the bleeding risk. As an example,",
"      <strong>",
"       some",
"      </strong>",
"      patients with ITP often tolerate very low platelet counts without bleeding, while patients with some acute leukemias that are associated with coagulopathy (eg, acute promyelocytic leukemia) can have bleeding at higher platelet counts (eg, 30,000 to",
"      <span class=\"nowrap\">",
"       50,000/microL).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H558395341\">",
"       'Specific clinical scenarios'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Compared with adults, children with bone marrow suppression may be more likely to experience bleeding at the same degree of thrombocytopenia. In a secondary subgroup analysis of the PLADO trial, in which patients were randomly assigned to different platelet doses, children had more days of bleeding, more severe bleeding, and required more platelet transfusions than adults with similar platelet counts [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/13\">",
"       13",
"      </a>",
"      ]. However, these findings do not suggest a different threshold for platelet transfusion in children, as the increased risk of bleeding was distributed across a wide range of platelet counts.",
"     </li>",
"     <li>",
"      Tests for platelet-dependent hemostasis (ie, bleeding time, thromboelastography, and other point of care tests) are generally not used to predict bleeding in thrombocytopenic patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H13#H13\">",
"       \"Platelet function testing\", section on 'The in vivo bleeding time'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H14#H14\">",
"       \"Platelet function testing\", section on 'Instruments that simulate platelet function in vitro'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323107\">",
"    <span class=\"h2\">",
"     Therapeutic versus prophylactic transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;By convention, most authors use the term &ldquo;therapeutic transfusion&rdquo; to refer both to transfusion of platelets to treat active bleeding and transfusion of platelets in preparation for an invasive procedure that could cause bleeding. The term &ldquo;prophylactic transfusion&rdquo; is used to refer to platelet transfusion given to prevent spontaneous bleeding.",
"   </p>",
"   <p>",
"    We use prophylactic platelet transfusion to prevent spontaneous bleeding in most afebrile patients with platelet counts below",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    due to bone marrow suppression. We use higher thresholds (ie,",
"    <span class=\"nowrap\">",
"     30,000/microL)",
"    </span>",
"    in patients who are febrile or septic. Patients with acute promyelocytic leukemia (APL) have a coexisting coagulopathy, and we use a platelet transfusion threshold of 30,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    for them. (See",
"    <a class=\"local\" href=\"#H558395349\">",
"     'Leukemia and chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with platelet consumption disorders (eg, immune thrombocytopenic purpura, disseminated intravascular coagulation) and platelet function disorders are typically transfused only for bleeding or, in some cases, invasive procedures. Platelets should not be withheld in bleeding patients with these conditions due to fear of &ldquo;fueling the fire&rdquo; of thrombus formation. (See",
"    <a class=\"local\" href=\"#H558395722\">",
"     'Immune thrombocytopenic purpura (ITP)'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H558395714\">",
"     'TTP-HUS, HIT, and DIC'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H323385\">",
"     'Platelet function defects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the need to balance the risk of spontaneous bleeding with the potential complications of unnecessary platelet transfusion, the decision of whether to transfuse platelets based upon a clinical event (ie, for active bleeding or invasive procedures) or at a particular threshold (ie, to prevent spontaneous bleeding) is challenging. Standard practice has evolved to transfusion of platelets at a threshold platelet count of 10,000 to",
"    <span class=\"nowrap\">",
"     20,000/microL",
"    </span>",
"    for most patients with severe hypoproliferative thrombocytopenia due to hematologic malignancies, cytotoxic chemotherapy, and hematopoietic cell transplant (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the risks and benefits of reserving platelet transfusion for active bleeding episodes in these patients continue to be evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/15-18\">",
"     15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, 400 patients with acute myeloid leukemia (AML; patients with APL were excluded) and patients undergoing autologous HCT for hematologic malignancies were assigned to receive platelet transfusions when morning platelet counts were",
"      <span class=\"nowrap\">",
"       &le;10,000/microL",
"      </span>",
"      or only for active bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/19\">",
"       19",
"      </a>",
"      ]. Patients transfused only for active bleeding received fewer platelet transfusions during the 14-day period after induction or consolidation chemotherapy (1.63 versus 2.44 per patient, a 33.5 percent reduction). However, among patients with AML who were transfused only for active bleeding, there were more episodes of major bleeding (six cerebral, four retinal, and one vaginal) and there were two fatal intracranial hemorrhages compared with four retinal hemorrhages among patients transfused for a platelet count",
"      <span class=\"nowrap\">",
"       &le;10,000/microL.",
"      </span>",
"      Patients undergoing HCT also experienced more bleeding episodes when transfused only for active bleeding, but most of these were minor.",
"     </li>",
"     <li>",
"      In another randomized trial, 600 patients with hematologic malignancies were assigned to receive platelet transfusion for a platelet count",
"      <span class=\"nowrap\">",
"       &le;10,000/microL",
"      </span>",
"      or only for active bleeding (the Trial of Prophylactic Platelets [TOPPS]) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. Preliminary results (presented in abstract) indicate that patients transfused for active bleeding received fewer platelet transfusions during the 30-day period after randomization, but had a higher incidence of major bleeding (50 versus 43 percent) and a shorter time to first bleed (1.2 versus 1.7 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/22\">",
"       22",
"      </a>",
"      ]. There were no differences in the duration of hospitalization. In a predefined subgroup analysis, patients undergoing autologous HCT had similar rates of major bleeding whether they were transfused for a platelet count",
"      <span class=\"nowrap\">",
"       &le;10,000/microL",
"      </span>",
"      or only for active bleeding (45 and 47 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings from these trials support continued use of prophylactic transfusion for patients with hematologic malignancies and HCT until further data become available. Although the findings suggest that reserving platelet transfusion for active bleeding may be safe for some patients with HCT, such a strategy requires intensive monitoring and the ability to perform immediate imaging for suspected CNS or ocular bleeding. We do not recommend reserving platelet transfusion for active bleeding in patients with HCT outside of highly specialized centers with the ability to support this level of vigilance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558395341\">",
"    <span class=\"h1\">",
"     SPECIFIC CLINICAL SCENARIOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several common clinical scenarios that raise the questions of whether to transfuse patients prophylactically to prevent bleeding, and, if prophylactic transfusion is used, of what platelet count is the best threshold for transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558395349\">",
"    <span class=\"h2\">",
"     Leukemia and chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with leukemia, hematopoietic cell transplant (HCT), or those being treated with cytotoxic chemotherapy have a suppressed bone marrow that cannot produce adequate platelets. We use prophylactic transfusion in these settings. The thresholds suggested below apply to patients with thrombocytopenia who are afebrile and without active infection. If fever or sepsis is present, higher thresholds may be needed.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Acute myeloid leukemia (AML)",
"      </strong>",
"      &mdash; Patients with AML can have suppressed bone marrow from AML, chemotherapy, or HCT. We use standard dose prophylactic transfusion of these patients at a threshold platelet count of",
"      <span class=\"nowrap\">",
"       10,000/microL,",
"      </span>",
"      and transfusion for any bleeding greater than petechial bleeding. (See",
"      <a class=\"local\" href=\"#H382870473\">",
"       'Dose'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      This approach is in line with the 2001 American Society for Clinical Oncology (ASCO) guidelines (",
"      <a class=\"graphic graphic_table graphicRef52206 \" href=\"UTD.htm?11/29/11741\">",
"       table 1",
"      </a>",
"      ). It is supported by randomized trials comparing prophylactic (ie, threshold-based) and therapeutic platelet transfusion, in which patients who did not receive prophylactic transfusion had more severe bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/19,22,23\">",
"       19,22,23",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H323107\">",
"       'Therapeutic versus prophylactic transfusion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the complications of acute myeloid leukemia\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Acute promyelocytic leukemia (APL)",
"      </strong>",
"      &mdash; Patients with APL differ from other patients with AML because they often have an associated coagulopathy that puts them at high risk for disseminated intravascular coagulation and bleeding. We prophylactically transfuse these patients at a platelet count of 30,000 to",
"      <span class=\"nowrap\">",
"       50,000/microL,",
"      </span>",
"      and treat any sign of bleeding, especially central nervous system bleeding, with immediate platelet transfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Acute lymphoblastic leukemia (ALL)",
"      </strong>",
"      &mdash; Patients with ALL have thrombocytopenia from bone marrow suppression. In addition, these patients are often treated with L-asparaginase, which causes severe hypofibrinogenemia. However, the risk of life-threatening bleeding is low. As an example, in over 2500 children with ALL, only two intracranial hemorrhages occurred, and they were associated with hyperleukocytosis in one case and intracerebral fungal infection in the other [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/8\">",
"       8",
"      </a>",
"      ]. We transfuse adults with ALL at a threshold platelet count of",
"      <span class=\"nowrap\">",
"       10,000/microL.",
"      </span>",
"      The use of platelet transfusion in children with ALL is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the treatment of acute lymphoblastic leukemia in children\", section on 'Bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Chemotherapy for solid tumors",
"      </strong>",
"      &mdash; Cancer chemotherapy often makes patients thrombocytopenic from bone marrow suppression. Randomized trials of platelet transfusion threshold in this population have not been performed. Observational studies support a prophylactic platelet transfusion threshold of",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/23\">",
"       23",
"      </a>",
"      ]. A threshold of",
"      <span class=\"nowrap\">",
"       20,000/microL",
"      </span>",
"      may be appropriate for patients with necrotic tumors. These recommendations are generally consistent with the ASCO 2001 Guidelines (",
"      <a class=\"graphic graphic_table graphicRef52206 \" href=\"UTD.htm?11/29/11741\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Hematopoietic cell transplant (HCT)",
"      </strong>",
"      &mdash; Chemotherapy and radiation therapy administered as part of the conditioning regimen for HCT can be highly bone marrow suppressive, depending on the doses used. We use standard dose prophylactic transfusion of these patients at a threshold platelet count of",
"      <span class=\"nowrap\">",
"       10,000/microL,",
"      </span>",
"      and therapeutic transfusion for any bleeding greater than petechial bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link&amp;anchor=H876315#H876315\">",
"       \"Hematopoietic support after hematopoietic cell transplantation\", section on 'Platelet transfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Aplastic",
"      </strong>",
"      <strong>",
"       anemia",
"      </strong>",
"      &mdash; Patients with aplastic anemia do not have a malignancy, but they may have severe thrombocytopenia, and they may be candidates for HCT. Issues related to platelet transfusion in these patients are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"       \"Aplastic anemia: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558395722\">",
"    <span class=\"h2\">",
"     Immune thrombocytopenic purpura (ITP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with immune thrombocytopenia produce anti-platelet antibodies that destroy circulating platelets and megakaryocytes in the bone marrow. Circulating platelets in patients with ITP tend to be highly functional, and platelet counts tend to be well above",
"    <span class=\"nowrap\">",
"     30,000/microL.",
"    </span>",
"    Bleeding is rare even in patients with severe thrombocytopenia (ie, platelet count",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our general approach to platelet transfusion in patients with ITP is to transfuse for bleeding rather than at a specific platelet count. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Platelet transfusions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558395714\">",
"    <span class=\"h2\">",
"     TTP-HUS, HIT, and DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS),",
"    <strong>",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    induced thrombocytopenia (HIT), and disseminated intravascular coagulation (DIC) are all associated with platelet consumption, and they can cause thrombosis as well as bleeding. The risk of thrombosis makes some clinicians worry that platelet transfusion will &ldquo;fuel the fire&rdquo; of thrombus formation. However, platelet transfusion can be lifesaving in patients with these conditions who are bleeding, and platelets should",
"    <strong>",
"     not",
"    </strong>",
"    be withheld from bleeding patients due to this fear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       TTP-HUS",
"      </strong>",
"      &mdash; Patients with TTP-HUS are at risk for thrombosis and bleeding. These patients can also require an invasive procedure that cannot be postponed until the underlying disease has been resolved (eg, central line placement for plasma exchange therapy).",
"      <br/>",
"      <br/>",
"      While it is prudent to avoid unnecessary transfusion in patients with TTP-HUS, withholding platelets from patients who are bleeding or need an invasive procedure due to fear of &ldquo;fueling the fire&rdquo; is not well supported [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H12#H12\">",
"       \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Platelet transfusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       HIT",
"      </strong>",
"      &mdash; HIT is a form of antibody mediated platelet destruction associated with inappropriate platelet activation. Patients with HIT are at risk for thrombosis and bleeding. Prophylactic platelet transfusion is typically not used in this setting, but platelet transfusion for bleeding may be appropriate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H43#H43\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Platelet transfusions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Liver disease and DIC",
"      </strong>",
"      &mdash; Patients with liver disease and DIC have a complex mixture of procoagulant and anticoagulant defects along with thrombocytopenia, and therefore they are at risk for thrombosis and bleeding. There is no evidence to support the administration of platelets in these patients if they are not bleeding. However, platelet transfusion is justified in patients who have serious bleeding, are at high risk for bleeding (eg, after surgery), or require invasive procedures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link&amp;anchor=H5813474#H5813474\">",
"       \"Coagulation abnormalities in patients with liver disease\", section on 'Bleeding risk assessment, prophylaxis, and active bleeding'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Platelet transfusion and fresh frozen plasma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323385\">",
"    <span class=\"h2\">",
"     Platelet function defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet function defects can be inherited or acquired, and may be associated with thrombocytopenia or a normal platelet count. Platelet transfusion in these settings is typically reserved for bleeding.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Inherited diseases",
"      </strong>",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Platelet function is impaired in Wiskott-Aldrich syndrome, Glanzmann thrombasthenia, and Bernard-Soulier syndrome. Bleeding in patients with these conditions is treated with platelet transfusion, along with other hemostatic agents discussed below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H26#H26\">",
"       \"Congenital and acquired disorders of platelet function\", section on 'Inherited disorders of platelet function'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6756867\">",
"       'Alternatives to platelet transfusion'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Acquired conditions",
"      </strong>",
"      &mdash; Uremia, diabetes mellitus, myeloproliferative disorders, and other medical conditions can impair platelet function. Bleeding risk can be reduced by treating the underlying condition. Platelet transfusion is typically reserved for major bleeding in these conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H20#H20\">",
"       \"Congenital and acquired disorders of platelet function\", section on 'Acquired platelet functional disorders'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients who are febrile or septic can have impaired platelet function. We transfuse these patients for bleeding. We also use a higher threshold for when fever or sepsis coexist with thrombocytopenia (eg, in patients with leukemia). (See",
"      <a class=\"local\" href=\"#H558395349\">",
"       'Leukemia and chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Antiplatelet agents",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      , nonsteroidal antiinflammatory drugs (NSAIDs),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      , ADP receptor (P2Y12) inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      ), and",
"      <span class=\"nowrap\">",
"       GPIIb/IIIa",
"      </span>",
"      antagonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      ) are used to prevent thrombosis by interfering with normal platelet function. The antiplatelet effects of these agents are weakest with aspirin and more potent with the P2Y12 inhibitors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=see_link&amp;anchor=H3#H3\">",
"       \"Platelet biology\", section on 'Drugs with antiplatelet actions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Typically, the approach to treating mild bleeding in a patient taking an antiplatelet agent is to discontinue the drug, assuming a favorable risk-benefit ratio. Although data are limited, platelet transfusion appears to be the best option in patients taking antiplatelet agents who experience severe bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients taking these agents may also require urgent surgical procedures (eg, coronary artery bypass grafting, neurosurgical interventions, and others). The role of platelet transfusion in this setting is not well defined. Some clinicians give prophylactic platelet transfusions to patients taking antiplatelet drugs who require major surgery, while other clinicians use platelet transfusion only to treat excessive surgical bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. These cases can be complex, and we favor an individualized approach based on the complete clinical picture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106617583\">",
"    <span class=\"h2\">",
"     Massive blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with massive blood loss from surgery or trauma are transfused with red blood cells (RBC), resulting in partial replacement of the blood volume with a product lacking platelets and clotting factors. In this setting, we transfuse RBC, fresh frozen plasma (FFP), and random donor platelet units in a 1:1:1 ratio. As an example, a patient transfused with six units of RBC would also receive six units of pooled platelets or one apheresis unit (both of which provide approximately 5 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets) and six units of FFP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H3250855#H3250855\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of blood products'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H323466\">",
"    <span class=\"h2\">",
"     Cardiopulmonary bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo prolonged cardiopulmonary bypass can have thrombocytopenia and impaired platelet function. The use of platelet transfusion in the cardiopulmonary bypass setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H22#H22\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Cardiopulmonary bypass'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H8#H8\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870465\">",
"    <span class=\"h1\">",
"     ORDERING PLATELETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several parameters can be specified when ordering platelets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870473\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard dose of platelets for prophylactic therapy in adults is approximately one random donor unit per 10 kg of body weight, which translates to four to six units of pooled platelets or one apheresis unit, both providing approximately 3 to 4 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/2\">",
"     2",
"    </a>",
"    ]. A standard pediatric dose is 5 to 10",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"    For prophylactic transfusion there is generally no reason to transfuse platelets more often than once a day. This platelet dosing is expected to raise the platelet count by approximately",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    within 10 minutes of the infusion. (See",
"    <a class=\"local\" href=\"#H382870688\">",
"     'Platelet count increment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical trials comparing standard platelet dosing with other doses have been limited to patients with hypoproliferative thrombocytopenia due to bone marrow suppression (eg, leukemia, hematopoietic cell transplant, or chemotherapy). Two large studies that evaluated the use of higher or lower platelet doses in these groups have conflicting results, as illustrated below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Strategies for Transfusion of Platelets (SToP) trial, patients with hypoproliferative thrombocytopenia were randomly assigned to receive platelet transfusion at standard dose (3 to 6 x 10",
"      <sup>",
"       11",
"      </sup>",
"      platelets, equivalent to approximately 5 to 10 units) or half dose (1.5 to 3 x 10",
"      <sup>",
"       11",
"      </sup>",
"      platelets, equivalent to approximately 3 to 5 units) when platelet counts fell below a trigger value (most participating institutions used",
"      <span class=\"nowrap\">",
"       10,000/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/28\">",
"       28",
"      </a>",
"      ]. The trial was halted prematurely (at 119 patients) because of life-threatening bleeding or bleeding requiring transfusion in the low dose arm (3 of 58 patients versus none of 61 in the standard dose arm).",
"     </li>",
"     <li>",
"      In the PLAtelet DOse (PLADO) trial, 1272 patients with thrombocytopenia due to chemotherapy or HCT were randomly assigned to receive standard dose (2.2 x 10",
"      <sup>",
"       11",
"      </sup>",
"      platelets per m",
"      <sup>",
"       2",
"      </sup>",
"      ), half dose (1.1 x 10",
"      <sup>",
"       11",
"      </sup>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      ), or double dose (4.4 x 10",
"      <sup>",
"       11",
"      </sup>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"      ) platelet transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/12\">",
"       12",
"      </a>",
"      ]. The primary endpoint of prolonged mucosal or deep bleeding was similar among all groups (67 to 69 percent). The half dose group received a higher median number of platelet transfusions during the 30-day study period (five in the half dose group versus three in the other groups) but received fewer platelets overall (9.25 &times; 10",
"      <sup>",
"       11",
"      </sup>",
"      versus 11.25 &times; 10",
"      <sup>",
"       11",
"      </sup>",
"      and 19.63 &times; 10",
"      <sup>",
"       11",
"      </sup>",
"      in the standard and double dose groups, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these conflicting results and the logistical issues associated with more frequent platelet transfusion, most centers continue to use standard dose transfusion until further data become available.",
"   </p>",
"   <p>",
"    In contrast to prophylactic transfusion, patients who are being transfused therapeutically (ie, for active bleeding or in preparation for an invasive procedure), or who have a rapidly dropping platelet count, may require higher dose or more frequent platelet transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870481\">",
"    <span class=\"h2\">",
"     Pooled versus apheresis platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platelet count increment and hemostatic effects of pooled and apheresis platelets are comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apheresis platelets have the advantages of limiting the recipient exposure to a single donor, which potentially reduces the possibility of infection and alloimmunization; some centers use apheresis platelets exclusively. Many believe it is logistically easier to perform bacterial testing on apheresis platelets compared with pooled platelets. (See",
"    <a class=\"local\" href=\"#H382870592\">",
"     'Complications of platelet transfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Use of apheresis platelets also permits transfusion of platelets from specific donors selected based on HLA matching or platelet cross-matching, CMV status, and ABO group. Patients with confirmed immune mediated platelet refractoriness due to anti-HLA antibodies should receive HLA-matched platelets or platelets negative for the corresponding antigen(s) or cross-match compatible platelets; in other cases, either pooled and apheresis platelets can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558381857\">",
"    <span class=\"h2\">",
"     Leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoreduction removes most of the contaminating white blood cells (WBC) from the platelet transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/30\">",
"     30",
"    </a>",
"    ]. In some centers leukoreduction is standard practice. In other centers, leukoreduction is used for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction of HLA alloimmunization",
"     </li>",
"     <li>",
"      Reduction of CMV transmission",
"     </li>",
"     <li>",
"      Reduction of transfusion-associated immunomodulation",
"     </li>",
"     <li>",
"      Reduction of lung injury during and after cardiopulmonary bypass",
"     </li>",
"     <li>",
"      Reduction of febrile nonhemolytic transfusion reactions (FNHTR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Leukoreduction is done by passing platelets through a filter that blocks passage of most white blood cells. Apheresis platelets can be leukoreduced during collection, and pooled platelets can be leukoreduced shortly after collection or at bedside before transfusion.",
"   </p>",
"   <p>",
"    Leukoreduction can reduce the risks of several potential complications of contaminating WBC, but it is",
"    <strong>",
"     not",
"    </strong>",
"    adequate to prevent transfusion-associated graft-versus-host disease (ta-GVHD), because some WBC can pass through the leukoreduction filter. Therefore, irradiation must be used to prevent ta-GVHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H10#H10\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Graft-versus-host disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H10#H10\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leukoreduction at the bedside (ie, post storage) is not optimal for reducing FNHTR because bedside leukoreduction does not remove cytokines released from WBC during storage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H3#H3\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Febrile nonhemolytic transfusion reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only drawback of leukoreduction is the cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558381864\">",
"    <span class=\"h2\">",
"     Irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet irradiation is used to prevent ta-GVHD, in which contaminating WBCs attack host tissues and cause serious, even fatal, outcomes in both immunosuppressed and some immunocompetent individuals. Irradiation damages the nuclei of donor lymphocytes in the transfusion, so that they cannot proliferate and mount an immune response against the recipient. Platelets are anucleate, so their functions are unaffected by irradiation, although there may be a slight effect on platelet survival due to membrane damage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/31\">",
"     31",
"    </a>",
"    ]. Platelets are irradiated by exposing the bag to 25 Gy from a Cesium source.",
"   </p>",
"   <p>",
"    Irradiation is not a substitute for leukoreduction, because lymphocytes inactivated by irradiation still express human leukocyte antigens (HLA) on their surfaces and can elicit an anti-HLA antibody response from the host. Irradiation is also inadequate to kill pathogens such as bacteria and viruses. Irradiation is used for the following indications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunosuppression or imminent immunosuppression from hematopoietic cell transplant, solid organ transplant, and cytotoxic chemotherapy",
"     </li>",
"     <li>",
"      Congenital immunodeficiency (eg, DiGeorge syndrome, Wiskott-Aldrich syndrome, Leiner&rsquo;s disease, 5&rdquo; nucleotidase deficiency) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H22#H22\">",
"       \"Medical management of immune deficiency\", section on 'Blood products'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       Fludarabine",
"      </a>",
"      therapy",
"     </li>",
"     <li>",
"      Hodgkin lymphoma and other hematologic malignancies",
"     </li>",
"     <li>",
"      Neonatal exchange transfusion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H47#H47\">",
"       \"Neonatal thrombocytopenia\", section on 'Preparation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Premature, low birth weight neonates (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link&amp;anchor=H4#H4\">",
"       \"Neonatal thrombocytopenia\", section on 'Neonates admitted to the NICU'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intrauterine transfusion",
"     </li>",
"     <li>",
"      A subset of donor-recipient pairs who may be closely, but not completely, HLA matched (ie, relatives and genetically homogeneous populations) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/35\">",
"       35",
"      </a>",
"      ]. The rationale for this is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H4#H4\">",
"       \"Transfusion-associated graft-versus-host disease\", section on 'Partial HLA matching'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Irradiation may not be necessary if platelets have been subjected to pathogen reduction protocols that also prevent lymphocyte proliferation (eg, photochemical treatments) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/35\">",
"     35",
"    </a>",
"    ]. These protocols, which have the added advantage of not requiring a radioactive source, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link&amp;anchor=H14#H14\">",
"     \"Preparation of blood components\", section on 'Pathogen reduction'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558381871\">",
"    <span class=\"h2\">",
"     CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some CMV seronegative transfusion recipients (eg, immunosuppressed patients) are at greater risk of adverse outcomes from receiving CMV-contaminated blood products than the general population. The AABB (formerly the American Association of Blood Banks) considers transfusion of platelets from CMV negative donors to be equivalent to leukoreduction in reducing this risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link&amp;anchor=H22#H22\">",
"     \"Medical management of immune deficiency\", section on 'Blood products'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558381883\">",
"    <span class=\"h2\">",
"     ABO, Rh, and HLA matching",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABO and HLA compatible platelets appear to cause a greater platelet count increment in the recipient, and they can be used to improve responses in patients who have become refractory to platelet transfusion due to alloimmunization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H12#H12\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Management of the alloimmunized patient'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to inventory constraints, most transfusion services issue ABO mismatched platelets when type-specific platelet products are not available. Clinically significant hemolytic transfusion reactions secondary to transfusion of ABO-incompatible platelet products (eg, group O platelets given to group A patient) are uncommon, but they do occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To limit such hemolytic reactions, some transfusion services monitor and limit the volume of ABO incompatible plasma given to a patient via platelet transfusions, or volume reduce or wash the ABO incompatible platelet products to reduce the plasma content. Some also screen for platelet products with high anti-A or anti-B titers and give products with high titers only to group O patients. However, the critical threshold has not been determined for either the volume of incompatible plasma or the",
"    <span class=\"nowrap\">",
"     anti-A/B",
"    </span>",
"    titers.",
"   </p>",
"   <p>",
"    HLA matched platelets can cause transfusion-associated graft-versus-host disease (ta-GVHD) so they",
"    <strong>",
"     must",
"    </strong>",
"    be irradiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H4#H4\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Partial HLA matching'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transfusion of platelets from Rh",
"    <sup>",
"     -",
"    </sup>",
"    donors to Rh",
"    <sup>",
"     -",
"    </sup>",
"    females of childbearing age is used to prevent alloimmunization and hemolytic disease of the newborn. If platelets from Rh",
"    <sup>",
"     +",
"    </sup>",
"    donors are used, the risk of alloimmunization remains low. In a retrospective analysis of 1014 Rh",
"    <sup>",
"     -",
"    </sup>",
"    patients who received 6043 platelet transfusions from Rh",
"    <sup>",
"     +",
"    </sup>",
"    donors (89 percent from pooled platelets), no patients who received only apheresis platelets developed anti-RhD antibodies, and 3.8 percent who received pooled platelets developed anti-RhD antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To further reduce the risk of alloimmunization if only Rh",
"    <sup>",
"     +",
"    </sup>",
"    platelets are available, Rh immune globulin can be coadministered with platelet transfusions. A single dose of Rh immune globulin can be given regardless of the number of platelet units transfused. If necessary, this can be repeated once every eight weeks (ie, a similar interval to that used to prevent hemolytic disease of the newborn). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16713966\">",
"    <span class=\"h2\">",
"     Other special modifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known IgA deficiency who have a history of anaphylactic transfusion reactions or demonstrate anti-IgA antibodies can be transfused with platelets that have been washed to remove IgA-containing plasma or obtained from donors found to be IgA deficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link&amp;anchor=H24166172#H24166172\">",
"     \"Selective IgA deficiency: Management and prognosis\", section on 'Safe administration of blood products'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, volume-reduced platelets can be used when exposure to ABO incompatible plasma needs to be limited, or for transfusion of volume-sensitive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5104767\">",
"    <span class=\"h2\">",
"     Infusion rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;For an average sized adult, six units of pooled platelets or one apheresis unit of platelets is transfused over approximately 20 to 30 minutes. Patients at risk for transfusion associated circulatory overload (TACO) can be transfused at a slower rate as long as the transfusion is completed within four hours of issuance from the blood bank. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870592\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF PLATELET TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet transfusion carries several risks, which include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Infection",
"      </strong>",
"      &mdash; Donor screening procedures and pathogen inactivation do not completely eliminate the risk of bacterial and other bloodborne infections, and infection by bacterially contaminated platelets represents a serious hazard of platelet transfusion. Platelets are stored at room temperature, where bacteria can proliferate rapidly [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Therefore, the incidence of bacterial contamination is higher for platelets than for red blood cells (RBC) (eg, approximately 1 in 2000 for platelets versus 1 in 30,000 for RBC) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"       \"Transfusion transmitted bacterial infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Transfusion-related acute lung injury (TRALI)",
"      </strong>",
"      &mdash; Transfusion of any blood product, including platelets, can lead to transfusion-related acute lung injury (TRALI), a form of acute lung injury that causes respiratory distress following transfusion. The true incidence of TRALI from platelet transfusion is unknown; it has decreased since institution of TRALI mitigation strategies in the late 2000s [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link&amp;anchor=H1588903#H1588903\">",
"       \"Transfusion-related acute lung injury (TRALI)\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Transfusion-associated circulatory overload (TACO)",
"      </strong>",
"      &mdash; Transfusion of any blood product may be associated with circulatory overload. Platelet transfusion introduces approximately 200 mL of intravascular volume per transfusion. The incidence of TACO is in the range of one to three per 100,000 transfusions and is higher in patients predisposed to volume overload (eg, with comorbidities such as congestive heart failure, renal failure, respiratory failure, and positive fluid balance). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"       \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Alloimmunization",
"      </strong>",
"      &mdash; Platelets express Class I human leukocyte antigen (HLA) antigens, which can be recognized by the recipient&rsquo;s immune system as foreign. Production of anti-HLA antibodies can adversely affect the response to future platelet transfusions. The incidence of alloimmunization depends on the number of transfusions a patient has received. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H16695453#H16695453\">",
"       \"Refractoriness to platelet transfusion therapy\", section on 'Immune causes'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H382870688\">",
"       'Platelet count increment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Allergic and anaphylactic reactions",
"      </strong>",
"      &mdash; Allergic reactions to platelet transfusion are relatively common. They are usually due to IgE directed against proteins in the donor plasma. Common symptoms include urticaria and pruritus in mild cases, and wheezing, shortness of breath and hypotension in more severe cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H14610169#H14610169\">",
"       \"Immunologic blood transfusion reactions\", section on 'Hypotensive reactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H16#H16\">",
"       \"Immunologic blood transfusion reactions\", section on 'Urticarial (allergic) reactions'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Anaphylactic reactions (ie, severe allergic reactions) are a very rare complication of platelet transfusion. These are associated with rapid onset of shock, angioedema, and respiratory distress. Many cases occur due to the production of anti IgA antibodies in recipients who are IgA deficient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H13#H13\">",
"       \"Immunologic blood transfusion reactions\", section on 'Anaphylactic reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Febrile non-hemolytic transfusion reactions (FNHTR)",
"      </strong>",
"      &mdash; These reactions are mediated by various inflammatory mediators and leukocytes and may manifest as fevers, chills, and rigors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H3#H3\">",
"       \"Immunologic blood transfusion reactions\", section on 'Febrile nonhemolytic reactions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Ta-GVHD",
"      </strong>",
"      &mdash; Transfusion-associated graft-versus-host disease (ta-GVHD) can occur with any type of transfusion that contains lymphocytes, given the correct immunologic setting. Its incidence continues to drop due to irradiation of blood products for at-risk patients, such as patients with hematopoietic cell transplantation, immunodeficiency, or other types of immunosuppression.",
"      <br/>",
"      <br/>",
"      A second and potentially less obvious situation that can lead to ta-GVHD in individuals who are completely immunocompetent is partial HLA matching (ie, a donor-recipient pair who are closely, but not completely, HLA matched, as can occur in relatives and genetically homogeneous populations) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/35\">",
"       35",
"      </a>",
"      ]. In this case, the HLA antigens on the donor lymphocytes are seen by the recipient lymphocytes as self, so recipient lymphocytes do not attack the donor lymphocytes; however, recipient cells also express unique HLA antigens that the donor lymphocytes recognize as foreign. This can result in donor lymphocytes destroying the recipient&rsquo;s tissues (eg, bone marrow, skin and liver), which can be fatal. (See",
"      <a class=\"local\" href=\"#H558381864\">",
"       'Irradiation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H17697373#H17697373\">",
"       \"Transfusion-associated graft-versus-host disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870688\">",
"    <span class=\"h1\">",
"     PLATELET COUNT INCREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a platelet transfusion, the platelet count should rise, with a peak at 10 minutes to one hour and a gradual decline over 72 hours. A general rule of thumb is that transfusion of six units of pooled platelets or one apheresis unit should increase the platelet count by approximately",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    in an adult of average size.",
"   </p>",
"   <p>",
"    Platelet count increment is typically measured within 24 hours in patients given prophylactic platelet transfusions. For patients undergoing invasive procedures, it is prudent to check that the desired platelet count was achieved before performing the procedure, which can be done within 10 minutes of the transfusion. For actively bleeding patients, cessation of bleeding is a more important clinical endpoint than the post-transfusion platelet count.",
"   </p>",
"   <p>",
"    The length of time platelets have been stored has a modest effect on their survival in the recipient. As an example, compared with platelets stored for two or three days, platelets stored for five days produce a smaller increment in platelet count. This information is not usually factored into assessment of a patient&rsquo;s response to platelet transfusion.",
"   </p>",
"   <p>",
"    Many patients who receive platelet transfusions reproducibly show a less-than-expected increase in platelet count. The definition of platelet refractoriness and its management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H16695481#H16695481\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Diagnostic approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H12#H12\">",
"     \"Refractoriness to platelet transfusion therapy\", section on 'Management of the alloimmunized patient'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6756867\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO PLATELET TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no substitutes for platelet transfusion to rapidly increase the platelet count in a bleeding patient. Reversal of thrombocytopenia due to autoimmune platelet destruction, platelet consumption, or bone marrow suppression can take days to weeks, depending on the underlying cause.",
"   </p>",
"   <p>",
"    Patients with ongoing bleeding not responsive to platelet transfusion and other interventions can also be given procoagulant bypass agents, such as prothrombin complex concentrates or recombinant factor VIIa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link&amp;anchor=H7704093#H7704093\">",
"     \"Platelet dysfunction in uremia\", section on 'Desmopressin (dDAVP)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=see_link&amp;anchor=H17#H17\">",
"     \"Medical management of the dialysis patient undergoing surgery\", section on 'Bleeding diathesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some settings, fibrinolytic inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    have been effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link&amp;anchor=H83049587#H83049587\">",
"     \"Coagulopathy associated with trauma\", section on 'Pharmaceutical hemostatic agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=see_link&amp;anchor=H27#H27\">",
"     \"Managing an episode of severe or prolonged uterine bleeding\", section on 'Tranexamic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stimulation of bone marrow megakaryocytes with thrombopoietin receptor agonists can take up to seven days (ie, the time it takes for new platelets to form). This might be appropriate for selected indications for preventing bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical applications of thrombopoietic growth factors\", section on 'Use of TPO receptor agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Investigational approaches to the use of platelet substitutes (eg, synthetic or acellular biological materials that could replace the primary hemostatic function of platelets) have not reached clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/6/20586/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H382870696\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A unit of platelets isolated from a unit of donated blood contains approximately 7 x 10",
"      <sup>",
"       10",
"      </sup>",
"      platelets, and four to six of these units are typically pooled for transfusion. Single donor (apheresis) platelets contain approximately 3 to 6 x 10",
"      <sup>",
"       11",
"      </sup>",
"      platelets (ie, the equivalent of six or more units) per unit. Platelets are stored at room temperature; consequently their shelf life is only approximately five days. (See",
"      <a class=\"local\" href=\"#H558382031\">",
"       'Platelet collection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H382870457\">",
"       'Platelet storage and pathogen reduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet transfusion can be lifesaving in bleeding patients with thrombocytopenia or reduced platelet function. Platelets should be transfused in any patient who is bleeding with a platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       (100,000/microL",
"      </span>",
"      for central nervous system or ocular bleeding), or in any patient with an acquired or inherited platelet function defect regardless of platelet count. Platelet transfusion may also be indicated in thrombocytopenic patients undergoing invasive procedures, depending on the procedure and the platelet count. (See",
"      <a class=\"local\" href=\"#H558395184\">",
"       'Actively bleeding patient'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H558384448\">",
"       'Preparation for an invasive procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other conditions that impair hemostasis (eg, coagulopathy, fever infection, anatomic defects) should be corrected in thrombocytopenic patients when possible to reduce active bleeding and to lessen the risk of spontaneous bleeding. (See",
"      <a class=\"local\" href=\"#H558395184\">",
"       'Actively bleeding patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We use prophylactic platelet transfusion to prevent spontaneous bleeding in most afebrile patients with platelet counts below",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      due to bone marrow suppression. Patients with acute promyelocytic leukemia (APL) have a coexisting coagulopathy, and we use a platelet transfusion threshold of 30,000 to",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      in these patients. We use higher thresholds in patients who are febrile or septic. (See",
"      <a class=\"local\" href=\"#H607102529\">",
"       'Prevention of spontaneous bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H323107\">",
"       'Therapeutic versus prophylactic transfusion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H558395341\">",
"       'Specific clinical scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with platelet consumption disorders (eg, immune thrombocytopenic purpura [ITP], thrombotic thrombocytopenic purpura-hemolytic uremic syndrome [TTP-HUS], disseminated intravascular coagulation [DIC], liver disease) and platelet function disorders are typically transfused only for bleeding or, in some cases, invasive procedures. Platelets should",
"      <strong>",
"       not",
"      </strong>",
"      be withheld in bleeding patients with these conditions due to fear of &ldquo;fueling the fire&rdquo; of thrombosis. (See",
"      <a class=\"local\" href=\"#H558395341\">",
"       'Specific clinical scenarios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Platelet transfusion has risks, including sepsis, transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), alloimmunization, allergic and anaphylactic transfusion reactions, febrile non-hemolytic transfusion reactions (FNHTR), and transfusion-associated graft-versus-host disease (ta-GVHD). (See",
"      <a class=\"local\" href=\"#H382870592\">",
"       'Complications of platelet transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Refractoriness to platelet transfusion is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link\">",
"       \"Refractoriness to platelet transfusion therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When ordering platelets, one should consider platelet dose, whether to use single donor versus random donor platelets, whether to include leukoreduction and irradiation, and whether to match CMV status or HLA, ABO, and Rh type. (See",
"      <a class=\"local\" href=\"#H382870465\">",
"       'Ordering platelets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are limited alternatives to platelet transfusion for the acute treatment of thrombocytopenia-associated bleeding. Longer term alternatives include discontinuation of drugs that affect platelet function, treatment of underlying conditions, and other strategies to increase platelet production. (See",
"      <a class=\"local\" href=\"#H558395184\">",
"       'Actively bleeding patient'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6756867\">",
"       'Alternatives to platelet transfusion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H323385\">",
"       'Platelet function defects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/1\">",
"      Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/2\">",
"      McCullough J. Overview of platelet transfusion. Semin Hematol 2010; 47:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/3\">",
"      Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability--deleterious effect of refrigerated storage. N Engl J Med 1969; 280:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/4\">",
"      Hoffmeister KM, Felbinger TW, Falet H, et al. The clearance mechanism of chilled blood platelets. Cell 2003; 112:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/5\">",
"      Hoffmeister KM, Josefsson EC, Isaac NA, et al. Glycosylation restores survival of chilled blood platelets. Science 2003; 301:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/6\">",
"      Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009; 15:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/7\">",
"      Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion 2011; 51:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/8\">",
"      Astwood E, Vora A. Personal practice: how we manage the risk of bleeding and thrombosis in children and young adults with acute lymphoblastic leukaemia. Br J Haematol 2011; 152:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/9\">",
"      Vavricka SR, Walter RB, Irani S, et al. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. Ann Hematol 2003; 82:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/10\">",
"      van Veen JJ, Nokes TJ, Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010; 148:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/11\">",
"      Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 2003; 48:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/12\">",
"      Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/13\">",
"      Josephson CD, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012; 120:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/14\">",
"      Estcourt LJ, Stanworth SJ, Murphy MF. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol 2011; 154:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/15\">",
"      Stanworth SJ, Hyde C, Brunskill S, Murphy MF. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now? Br J Haematol 2005; 131:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/16\">",
"      Friedmann AM, Sengul H, Lehmann H, et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002; 16:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/17\">",
"      Buhrkuhl DC. An update on platelet transfusion in hematooncology supportive care. Transfusion 2010; 50:2266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/18\">",
"      Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2012; 5:CD004269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/19\">",
"      Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380:1309.",
"     </a>",
"    </li>",
"    <li>",
"     A Randomised Controlled Trial of Prophylactic Vs No-Prophylactic Platelet Transfusions in Patients with Haematological Malignancies (TOPPS: Trial Of Prophylactic PlateletS) file://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=3825 (Accessed on August 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/21\">",
"      Stanworth SJ, Dyer C, Choo L, et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010; 24:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/22\">",
"      Simon J. Stanworth, Lise Estcourt, Gillian Powter, et al. The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. American Society of Hematology abstract book 2012; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/23\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/24\">",
"      Swisher KK, Terrell DR, Vesely SK, et al. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009; 49:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/25\">",
"      Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 2008; 48:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/26\">",
"      Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect? Transfusion 2012; 52:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/27\">",
"      Pandit TN, Sarode R. Blood component support in acquired coagulopathic conditions: is there a method to the madness? Am J Hematol 2012; 87 Suppl 1:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/28\">",
"      Heddle NM, Cook RJ, Tinmouth A, et al. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/29\">",
"      Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007; :172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/30\">",
"      Fast LD. Developments in the prevention of transfusion-associated graft-versus-host disease. Br J Haematol 2012; 158:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/31\">",
"      Rock G, Adams GA, Labow RS. The effects of irradiation on platelet function. Transfusion 1988; 28:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/32\">",
"      Przepiorka D, LeParc GF, Stovall MA, et al. Use of irradiated blood components: practice parameter. Am J Clin Pathol 1996; 106:6.",
"     </a>",
"    </li>",
"    <li>",
"     Webb IJ. Transfusion-associated graft-vs-host disease. In: Transfusion reactions, 3rd, Popovsky MA.  (Ed), American Association of Blood Banks Press, Bethesda, MD 2007. p.237.",
"    </li>",
"    <li>",
"     AABB Technical Manual, 17th, Roback JD, Grossman BJ, Harris T, et al.  (Eds), American Association of Blood Banks Press, Bethesda, MD 2011. p.237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/35\">",
"      King KE, Ness PM. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion 2011; 51:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/36\">",
"      Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have \"high-titer\" anti-A/A,B: implications for transfusion policy. Transfusion 2004; 44:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/37\">",
"      Cid J, Carbass&eacute; G, Pereira A, et al. Platelet transfusions from D+ donors to D- patients: a 10-year follow-up study of 1014 patients. Transfusion 2011; 51:1163.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Biologics Evaluation and Research, Food and Drug Administration. Workshop on bacterial contamination of platelets. Bethesda, MD: Food and Drug Administration, Center for Biologics Evaluation and Research; 1999. www.fda.gov/cber/minutes/workshop-min.htm (Accessed on November 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/39\">",
"      Centers for Disease Control and Prevention (CDC). Fatal bacterial infections associated with platelet transfusions--United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/40\">",
"      Kleinman S, Reed W, Stassinopoulos A. A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/41\">",
"      Jacobs MR, Smith D, Heaton WA, et al. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/42\">",
"      Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/43\">",
"      Kim HW, Greenburg AG. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others. Artif Cells Blood Substit Immobil Biotechnol 2006; 34:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/6/20586/abstract/44\">",
"      Okamura Y, Katsuno S, Suzuki H, et al. Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute. J Control Release 2010; 148:373.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7918 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-6660D27D4F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20586=[""].join("\n");
var outline_f20_6_20586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H382870696\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382870434\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558382031\">",
"      PLATELET COLLECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382870457\">",
"      PLATELET STORAGE AND PATHOGEN REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558384432\">",
"      INDICATIONS FOR PLATELET TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558395184\">",
"      Actively bleeding patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558384448\">",
"      Preparation for an invasive procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H607102529\">",
"      Prevention of spontaneous bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4185989\">",
"      - Predicting spontaneous bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323107\">",
"      Therapeutic versus prophylactic transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H558395341\">",
"      SPECIFIC CLINICAL SCENARIOS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558395349\">",
"      Leukemia and chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558395722\">",
"      Immune thrombocytopenic purpura (ITP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558395714\">",
"      TTP-HUS, HIT, and DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323385\">",
"      Platelet function defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106617583\">",
"      Massive blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H323466\">",
"      Cardiopulmonary bypass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382870465\">",
"      ORDERING PLATELETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H382870473\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H382870481\">",
"      Pooled versus apheresis platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558381857\">",
"      Leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558381864\">",
"      Irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558381871\">",
"      CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558381883\">",
"      ABO, Rh, and HLA matching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16713966\">",
"      Other special modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5104767\">",
"      Infusion rate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382870592\">",
"      COMPLICATIONS OF PLATELET TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382870688\">",
"      PLATELET COUNT INCREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6756867\">",
"      ALTERNATIVES TO PLATELET TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H382870696\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/29/11741\" title=\"table 1\">",
"      Platelet transfusion guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=related_link\">",
"      Managing an episode of severe or prolonged uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=related_link\">",
"      Medical management of the dialysis patient undergoing surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_6_20587="Efficacy of IFNa in chronic HBV";
var content_f20_6_20587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endpoints for assessing efficacy of IFNa in chronic HBV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Suppression of HBV replication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clearance of HBV DNA from serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clearance of HBeAg with or without the development anti-HBe antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Improvement in liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normalization in ALT level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in necroinflammatory activity on liver biopsies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Eradication of HBV (which is seldom achieved)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clearance of HBsAg with or without the development of anti-HBs antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clearance of HBV DNA from serum (by PCR); rare in patients who remain HBsAg positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disappearance of HBV DNA from liver",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prevention of cirrhosis and hepatocellular carcinoma and improvement in survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scanty data",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20587=[""].join("\n");
var outline_f20_6_20587=null;
var title_f20_6_20588="Indications pacing modes III";
var content_f20_6_20588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for different pacing modes - III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generally agreed upon indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Controversial indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDI",
"       </td>",
"       <td>",
"        Need for dual-chamber pacing in the presence of significant PSVT in the CC patient",
"       </td>",
"       <td>",
"        Sinus node dysfunction in the absence of AV block in the presence of of significant PSVT in the CC patient",
"       </td>",
"       <td>",
"        Chronotropic incompetence in the patient with a demonstrated need or improvement with rate responsiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDIR*",
"       </td>",
"       <td>",
"        AV block and sinus node dysfunction in the CI patient in the presence of significant PSVT",
"       </td>",
"       <td>",
"        Sinus node dysfunction without AV block in the CI patient in the presence of significant PSVT",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDD",
"       </td>",
"       <td>",
"        <p>",
"         AV block and sinus node dysfunction in the CC patient",
"        </p>",
"        <p>",
"         Need for AV synchrony to maximize cardiac output in CC active patients",
"        </p>",
"        <p>",
"         Previous pacemaker syndrome",
"        </p>",
"       </td>",
"       <td>",
"        For any rhythm disturbance when atrial sensing and capture is possible for the potential purpose of minimizing future atrial fibrillation and improved morbidity and survival",
"       </td>",
"       <td>",
"        <p>",
"         Presence of chronic atrial fibrillation, atrial flutter, giant inexcitable atrium or other frequent paroxysmal supraventricular tachyarrhythmias",
"        </p>",
"        <p>",
"         When adequate atrial sensing cannot be attained",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDDR",
"       </td>",
"       <td>",
"        AV block and sinus node dysfunction in the CI patient",
"       </td>",
"       <td>",
"        As for DDD",
"       </td>",
"       <td>",
"        As for DDD",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CC: chronotropically competent, ie, the ability to achieve an appropriate heart rate for a given physiologic activity; CI: chronotropically incompetent, ie, the inability to achieve an appropriate heart rate for a given physiologic activity; PSVT: paroxysmal supraventricular tachycardia.",
"     <br>",
"      * DDIR is being supplanted by DDD or DDDR pacemakers with the capability of mode-switching, ie, the pacemaker automatically reprograms to a mode incapable of tracking the atrial rhythm in the presence of an atrial rhythm that the pacemaker classifies as a pathological rhythm. When the pacemaker recognizes the atrial rhythm as being physiological, the pacemaker reprograms to the previously programmed mode.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20588=[""].join("\n");
var outline_f20_6_20588=null;
var title_f20_6_20589="Asparaginase desensitiz";
var content_f20_6_20589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50483&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Asparaginase desensitization*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 1:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 1 int. unit",
"       </p>",
"       <p>",
"        Accumulated total dose = 1",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 2:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 2 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 3",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 3:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 4 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 7",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 4:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 8 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 15",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 5:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 16 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 31",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 6:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 32 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 63",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 7:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 64 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 127",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 8:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 128 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 255",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 9:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 256 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 511",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 10:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 512 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 1023",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 11:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 1024 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 2047",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 12:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 2048 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 4095",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 13:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 4096 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 8191",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 14:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 8192 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 16,383",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 15:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 16,384 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 32,767",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 16:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 32,768 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 65,535",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 17:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 65,536 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 131,071",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Injection 18:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Elspar&reg; dose = 131,072 int. units",
"       </p>",
"       <p>",
"        Accumulated total dose = 262,143",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Some practitioners perform an asparaginase desensitization regimen for patients who react to a test dose, or who are being retreated following a break in therapy. Doses are doubled and given every 10 minutes until the total daily dose for that day has been administered. The suggested schedule as outlined above begins with a total of 1 unit given IV and doubles the dose every 10 minutes until the total amount given is the planned dose for that day. For example, if a patient was to receive a total dose of 4000 units, he/she would receive injections 1 through 12 during the desensitization.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Merck and Co, Inc. Elspar (Asparaginase). Densitization regimen. Copyright &copy;2008 Merck and Co, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20589=[""].join("\n");
var outline_f20_6_20589=null;
var title_f20_6_20590="Survival saphenous vein stent";
var content_f20_6_20590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Outcome in patients undergoing saphenous vein graft stenting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 475px; background-image: url(data:image/gif;base64,R0lGODlhYAHbAeYAAP///4CAgAAAAICA//+AgEBAQMDAwHBwcDAwMBAQENDQ0PDw8KCgoCAgIODg4LCwsP8AAFBQUJCQkGBgYP/AwP9AQAAzzKCg/8DA/xAQ//8QEP/w8P+goFBQ/wAA//Dw///g4P8gIP9QUP9gYNDQ/zAw//+QkP+wsEBA/4CZ5iAg/7Cw//8wMJCQ///Q0HBw/2Bg//Dz/P9wcODg/8DN8tDZ9hBAzyBN0kBm2aCz7LDA72CA3zBZ1uDm+XCN4pCm6VBz3L9AgO8AD/9fX/+/v/8/P4BwcK8AT/8fH28wv//f3//Pz38AAP9vb18wz2BQ7xAQgJ8AXyAQ71BQfw8Ab0BAgJ9AnzAg7oBw7+9AUK9Aj9+An78QUHBg74AQj08ArwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABgAdsBAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pm4BgqEDwESHAz6F1CfQWwKAggoMOiAAAQJEgh0CFHiwYvTCghYKGiBgAQAJAg44BGkyAMYU0IzwBEAS4YvX7psqbKmMpkzYS6UiVOQgQBAgxrA0GKGzaO5cCp4COCBgAhLETR9Suhn0AAFAmDokEEFjBUfkIqFpUAkAgMLADQQ8CCCAAZq/9m6hZsI6CAMA0p4KDEAw9i/qTRuFGAAgAIEH1EaRpxAcd0Ahj6sgKEiQ4cBmDNr9gu4cy27iWa00EwaxQDPqGWBXkSBgOvXBIIEgX2Cgm3bG1LrHrVaUWvYrmXDrkC8OITjyEMUJz4CuInbtl3snn6odyTMkFxAp2AC+IjlFUIgRw6+AmwOtqnXtA5pwAtUG7afGB7+uHLzJqSrv8f+0QoPF9xiGwcEiKCBBiLklw9uAMQHAiMcVKAfPf09cgGAvLhggoEIEkDBg/McJwIAFEBAACIVQCBIayBSCJklFwboi4bfHVdBcx+6g5xtJpIoAnEmkCiehyzO9yCBuUVYQf+Q6VQISYzDgNBajRDc6OGDrRGxxDgQsKBBCCf0SEBzKXLAgQZVEggBBRxAEOSXAMgAgQwiuNnki5dAeYyUY6YIgXhFIAEBEkU0QYQ3aVbZ4wYbstBjioIQsOYGGrDgQo9fulblnZrouQyfSgiiHQFDDAHcqaimquqqrKJKQSeb+nmilyaY8KiKAEj66ggQ8Prgn69xwGmnHrxAWl/O/Nbqssw2i6oII8BaAYnHnfgnBXKemOIJLugKQJibAlCnhwQOq8kKx5q2GwUsSCsIrye2qeiJJ6DZ3ZqCiCdsgyOgqcGJtaAVi5OaYLcbrvQQdgBdrRCcicG6sfBqwhE0kBX/UAyj4jAmEKc2ggjOhiwyqxPT4tBgGzGkysaXDGCaZit0puzINNdcMi2HTWDAzv2sjCcoeGn2Aob7wcNPwz+b4mnR6iiQwEYIpOXzKkszfU4DDQRwQAITrMLyJ1VbTQ5hgmDlddKohC12OA1EYMADCHQ9dStqr+0NA4Ml0HMqX4dSt93cJFTQ2bD8DXhnfYtyobHHcnb4WImLgm66pz0Ozz8BCCQIQZo/pkvHlkcj9SUTPPR0YRRF1Hl1aNMCeujPFFBAxpNstIBCAZQU0kiKRJ7K67A3czLXe0dSegMIRM0TTax//nJmjgevzAIMPP3QA5KY9ZECy6vs01VYtT5L/9CZqSu9MgocsJYAa3nvyFIMiVRAVFNFUBX4WQED/PnDaNTAAQJxAO0Y4YCPPKB0XVtLW97SO/HhYn/8C4YEsHcJBqyFa2k5TGIW4TtXQDCCv1iYICTgQFF0sBUfBOEuFmCAuO0sAu47xQlZ4bJj2fCGN4yeCkXBEpQJQG58K6EtyIfDItrQfDschQMCYDGgSGB0g8gfAA5gP0/MMBkpTOImFLA6QiyxiQFAQAw1cUVkZFGLl8gcA66SsR6iTIiUKOMxamhDHaKREoQRTMoIwUIXHu0TcjQGETWDxDtWAi3c29kfg3iOMxoSE9UbzBgzEUhnOPKRiPDhHgvxNNkVwP8xnKhkMy6Jjh78IAU/6EEPaFCDQdSABjEAQAxykIIU0OAWnswlKAXRGN7AcRukNEcOLHADHNjAAjUg5iBuYAMA1OCYPOCBBVJAjAMAERSiZEYwy2EBC8QSANS8gQV0AAAaWGAHABBnDgRRA3LWYn4H0KUh9Mi8TWRzGdskhzhvsIMcxPIH5wTADpCZTB7sIo8oG2M8PblLMv5SG/kcRw1w0E0L8CAGMbCADWJgA4OaEwcAoOg0zUUOOhoReuWIZQx0IM5bAsECFP2BLDUagxoMlJq3WEA8I0DBQmjQAA2QACAfmo1BGrGQ4bCBD2igAxtsFAA6qOg3fQBTHdwUF/T/7OkgKmKAeA4VHxGNxg7EaQEgtFIQ4kTnIFJAVhzc8hYCgMwCxGgIthTgJ5PExD2BWTlMEqIAFDQbJyUA2AZc055ETYdJT8rYxjr2sZCN7EntKAvZIcBiBWibIRQymMJYMbHoMKpkR0va0pq2iJSNhSbrOcIC8BSboPWrPgJgPwcA9quyvcgCSIgxQySALhPIaxpjm9t1uEWSdfWsYDux1+J6YyR5RFvyHvCAXn7WuQYhjESWO5C8ddGh2NXHbyuWgEkucXDXDS8+GMAAp+nNEAdoKCIwpznOcZC46o1HcBkx14ecZYqms4jn8msPDVq3EBJIQFAGKIjSCbUjH9md/3wH0VwCX6N9iEEbPfPayYc4oHsNtHA92CIIGBoikTzLJGEQCOJBWCUoUhSxPEQIANoe4h9LLB4hnpYT+jmlit+7Soxl7I7VKnQjBojAYQdRugA0OS4LZDCF8UtkbuSSob6dwFm4y8fjKsbAE55ylS+SRwPsN71jdscC3HLgv17WLQ9mLpXTrA2NFCDDJ7Ze1HBLZ3aQeIp5XSSa+6wOBQNgzUAeBJhhS2h2nGwjWhUEhuPK50ang7CvrSsFTTxoS5uDvb2ji5Mr7elycBoR9NwkYkuNDgsqUseAvnKY4zhnVkdjw4SzdTnWuOBc65ocLIS1DGv962bgDWpQHHaxx/+RgKw5ZMmDSHYoib1sZSTAs15FBFBz1+lqc0NrO5uA24RtWwPK2dvgSDVrq+LZVaP7buALgKjjLeXhvhsdRib1vcWhyH4LW6/U3jc0UPxvewvcHI9eN8APro2fBtW3GmHirCtRYYbngqvZJgRhBHC7RLvb4tawK1417Vq6dhvk0UgAYR9gWPgGwCkMPDnKn8FZJCdCAQU3+MypgelINxiAJgz4znUhsEQIBgEMkDYlhT50rP7Q5wNRn8IF8eG92TfETY8GAxDDvjj7YwLtS0R/VZY6ASOi4lmXhQLsPE+oPTERJ2OI7k6C9bQ7Y+sbUbkhJgB0RbBEIToJfN3tzgz/jUwA6o5YwP9A3BOX4I/phJdF0eeZPnkawo0p8zFVXPz4yC8Dkf7WuAFwbQgWGsAs/VDgXAbveWMgFLmHbMmiWd96YqiRjXvvO6NrnwwGeJa6bX9I0vXN+/69KOP+kLpwLYH24pMC8xvx+ObAPnXmQ975qFh7s2UHleAj4O0yx74vfK8Ivn932uIvxm57XQhQBz39xDiuqgdx6t3DPxjQHT3aXJ3i8N8/F9q1RGNEeuf2f8AwXg1QXobAa73lfwZoC+zlXrCGYoL2cQ+IDASIfhe4C/EmbwsYFALgdRa4gXClSctXANC2cCSYFP3Wf4SQSNW1fBR3fSvYCQzogYVA/0802Hw1eAkZKAgMWG8614O2gGK/dWL9IAFCaH1EyAuuZQgIcACchXhD2ISzwGsOMUZ5hAARIH1LZ4W2kFWaNhJcBl5giDOKdH7HxQBdSHxnmAsOEAEkcVsO+IaokGCwx0h2qFrlJTsTZ3976ApZ8wo8GIiMsG0NqIeG2ApcN3+QQD1A0TlXN2CLyApP8Wpx5F0AVhHnJ2aVyArWhAkGIBBukTsRRneU+ImBkVCk8xYtdnY0qIqMsFB+aAn084qOJ2SxKIulUD17pnmJ9mJAMWS8WAq0+EmUIBKN4YGqF3OwWIyo8IOPgGuzl4rQeAoNQIXvd42pYHKKyI2isFCI4f+FpFCI3KhHDZBzoWCO4EiIu9iOo0dBD3BXvtaOnjABIDEIXFOP9sgJsvNXMgiI/bgJBZAAUrMACjg3A8kJeJM1TBSC/LiQmVA6efiNEqkJCfFySHORzsCOHGkKHvmR5fiOImmRJVkMIXmSAqmSw5CSLFmAL2l7JBmT20iTwuCSNqmCOQkMOLmTM+iTr+AAJKSNngiUq+AAEYEYf9iTQOkQQvU0SkcITOmTGlEYVXlfRskKV3mV9yNkF9OBYBmWYjmWZFmWZnmWaJmWarmWbNmWbomW7eYMboE9iKFjwogVX/mW+JOXegljfNmXXgmYHSg7gumXhRmWhHmYY0mMzID/NzzFPozQXJL5jhW3V4UYklM5ClvzEOroEnE5gma4kqCpkzUJkjMJDpNZmjA5mnW4miqRmuu4i5Z5mph5mt8Am6IZmqzpmiOJFLjphl/Im8CZmwexM59gnKGAnMf5mZmgnDzEnKPgnFkZOpA4fM25N0IJEFHZCNkJfoLAPZ0YCWUhb6MDicQGnh2xRt5JCeaZnuSJCaanSGnRndtZCZC4nujZDYihEVJxCQlBE3rUn5MQoIr2NNTGiobRSQ3gnwZ6aPv5EfW5CE6zEAsKAA8qoLGHMlY5GBiaCWMHod/ZoNzwYwAwlz6oag+wAIpHNpOQoivqWVxHbXBRQAIgaQLQ/5mNEKMzIRVcOQlrYXVUYaKWYHrHJhAuuhbQGXs8yqI6+m2UhjuiyFprEZ6OMKU11hiU1pwOARlLgTWbF0dYKleIcVkp2Ahduhb2A6VQOpE/VAhWugn9RaZlE6bdoKZZagmNJ2GXQHdL8Q93WkEagRIscRaIsYQ3xxZQugD4uBZ7NgmD2kJvYafURqOrg4pwuqgPsQB9uqbbQHdOGaXu82yXIKo15kNCV5XwU6r4VXMbARCUVoqUkKq446kQiQkIRAikygkiARmlyKp/ig0F1ABAJQBUaqZmITBu4ZBJygjJChSjGG4/VKyHiABasxECoUCIsayL8GFmFq14Q6jOKP8J2EoYwTqs0nqI1kp/7OOsDPkQkMoA3IpA5woNFsQ+hsoI9FQYpopHb0RhvzoJDsB12fidjHGvHJSlmzmIlWBgdFGvDWCwixCoGtevnJCwP8Op05mxGruxHNuxHvuxIBuyIjuyJFuyJitigjaJk3iymfCf3lN2ExFg88qy+LpJczcSN/uHNOsIONE9uLizsacyPssRjXeXAaCtQOsTsscUPwaMXTmM9Ji0N3esadGMcGG1iLACVWCbNpmvi7FBX9tmhbACUDAFUitDVIACYXG2o2AETHAEUkACbGtCRiACQvAFLTC3jFYvR9AFa6u37rYBdpsEciuyUkRFvTkIJsD/BRmQWtP5RRfjjbFJCBsAAVjQASALff/aaSKwBRkAsn2kMxUokBwgAipQuCBLcIk7CJX7BH3lsQkXkKQpCCJgBSgQsh/BfqoJAByQBR4QsgprmoZQuVcQMx8bT5joS4cgAl7wHh8rjSd3AkLgBCB7gxD7k4fAAUIwIR3LQt67uoagBRrQIht7bC2ks1VICAMQBSyQGxyLPMJahuFHAiowAu3LsWWGfMQJABkwA8TxvloWAGI7nB3QAhvAAtGisTD3ETOLvYjQAph7wAmcsYLTwA58CCTwuQAAAhrAJFkZAVKBlDPpMBlQuC6gAftilH+mv8MJAAU8CCd8Alm5wrKb/76FAMGEYALtYpQR0BifqryKkMGFoAHcm5MKsD6N2gj0NRAAQaUbU8KEIAMTDJSjW36mQzYwa42H8MKDAAIQ4L47+Y+RYDu4k7NabAjuUQgJApTyuwjHkzwsRLRTtzErcLuEcAIh0JQLUYuNoD16g4vCKDtIiwElYAhgQpUIKqEcIT9Oy3l+ibQf8LuFsCEnW0AJcEBtirXPyAge8LeCULnkG5M6NT+Zxgj1ikFhO2ssUwJ2NAIysJPHZWbkqIGLgALGSwgnvJMheFdtTMuKYCyHwAIEAMYvKXJPCMSLsAJQXAgUUAEaMAI3c5L42Gzhur/qWwKe3MUEEAIhQAChzP+Rawa2yMwIHYC5iUAB/WIeBMABxCy1ffMBfLEIG0AgBQIBIOMsMhyI1bi7QZwBMtII8xwyCNLOVjhpIwxaGKACKGAUnyC4/1IbBL2Cf1Z/1nwIHzAAHjAA2bwJJyADFeAoXVIBMpDPJIiDozbOkDADKKACjrsJ8TEfyvHN96duNUxrltACKrDRobABkjLMF3iMfFzRtfy6pQAC4YEqKbyQZYQB/asK83EqyhHN7ShHMAADssDTzyzT0ChHM9C4swAC/eLTiKAdtuEaJA2GgeQytdDM3ezRxCEe9lEcMkAAGvDKAucAFmzTmPABKvACLb0K9HwbRUwIIMACLKDVvxb/EyhdCRgAA3pRAl8xDDKgAWddbbejESIonJdAFBngvMFQLxWA2L+W15BQYTNQAiXA0MCwAZMNMKzWgder16DwAl4tDOwiMdjAIA4CIRKCDfm22J1wAU09DHQtAxH9DCJCLa5dCJBCIt6MDS3ogpM7Ci9QyMRg1P/SLOxMDDtSIidCAT+yJEJiImUNAkbCuz6tJB68DOuXiNM9CiXg2cPw1MzizNAsDF3yJWFyImNCAGVyJmmiK23yJnksJ3RiJ8wgf9Wnm6HQ1f9MDSCwzd0s2rWQKClyIowiAo6iLbiiK5RiKZjSzZIyLcyQf4zZmpnwHw9eDeisARUg1bcQK9UC/wC0YiscHin4wiu+AgDA4hpJnQwB2Mu76QmGAw2MogHHTQubUiI9ci3ZAgDb0i34Ai4kPi5sstzJgIAJ6QhL3BRNTHuKQzTZIAIjsgvhAi+8ayM9Ui9u4i0AoC+f3C8Q8C/G1l4RgaMO6l+oI7NnHOYDgLrWQClzXTMk0xkRiggOFm2nyDubjAorwBWW0QKALg0zQ+ioYh6dcWfW6QgdhgAfJsfC1ZMkAMEZYBl/rQ6u0RmPpjOOgGQsBupPi5dIWwokMADLLA/+bem6viowngwLMI8Lro81+hKNHGRQO+umkBc6zQ6VvuvO7hq9fgzpsz5lWghN9mSa3DyzUM6G6P8/B4Dnh+ZlBCvO2i4L8EzUYDhBGsO1jpDBK56VmWkITP3uNfh6jtjCrJDBVm2F8GR5/BwL8NwBy76Bh67ZAN8B2MzvSFfwwZkLMHDrNbjqyG7DtSDcpw5/v852wG0LA2DONTjtG1HtDI4LQtyD3g7uTNgLEL+B6q5svcDFKxhf6+4LOFyDZya8vVDyK5hguvvevLDyDwi9Bm8LHfACA59+FIjyss0LW+EBHXDxtWe94NsLH9ACw22AQu/Lv1DdF2iEsT0J8T4J8b2Cx/zvvODgBoiFwT67wMDUeTvTKEOUDT8M9LvvSJ+GpRD2lQDPCS9+7LVmIj/yw0AZk157QUX/kZmN4rxg9bfMe4QhRiys+LygzG/PewoWV0Iu+MVQ98V3Mi0U+Gx/DHx/9Du3WykaAEoP9ux+CoTfj3rfCVYP9elXdUyMXuXuDMJd+Bc4doKQxY3+DDhN+hbnvZM3i3tkxr//DI5NeOYbhTwbV7Cep1K5+qsA2XYHvyPHX4sX/cwTyFEbDXxd+UOXv7ILffPDtF+ai8dODRk8AKo9c4ZFrQN8CKaHelC2eskfDVvRFV8BCB8Ag4SFhoeIiYqLjI2Oj5CRkpOUlYYPApkJDpEGAgWDCggCCQeLAQGWqqurGAMlHiUDGKy1tre4ubqsCgESnLuGqMHEtx8rMCoZHSvF/87P0NG6DwEOAQrPw9LbkTMDHhfc4uPk0QeZBhET2anl7ocX4O/z9PWOCRMIBgGgztr27uKFA0iwoDsBBgoYmNCv2D+D4gRCnEixWAEEDSIIkMCuYkQPzTyKHFlJQYJMCBZ0JBntxQCWMGMyMoAN2kOZuwa8xMkzZoGGNtv11KVzqFGR/LbdPMpqAIoLGDAIYkq13rmfBUz5E1q11YAOKFB4GBu2w6yuaKMVyJQJaLClaVl9iHrhRYapcfPeqiYOrt5aHTr8HbwKYQGuKwkbyxBSseNHCRpExqrVIeLHqi4IxsxZEYOTbD8l7mxpRgbSqA8dYKD0cupIJWi9fm1Nmv/f2Y1evMCd2pNt17wZYSgRnLTvaLeLJ8owQznm40GdQ+oAQ6f162elU11g4Ld2R66wXw/sWEeKFDoA0KARY1AMGjUG1Tifo8fQw4MORBj9nRKJ04PFwIMFOAyYAhAW5DBIDhb8AMAOFtiAgw0W8GRNA4cFgIBbuyTXnyMZkDBYChb4IJ8ODPIwCA4W9JBiewCkwJMnoQkAHC4efshIYOLJRhWDBKYQHwAU9tCDBUAAgGB6RnGHwAQG0BSdjpWEd10yaKVAoQUJAuCDBSn8YEF6LK7HZYVUEpJjmpCoMBBTMNbwJQ4A1GDBDTfYMMiXKbzH5VCfscWhLmuy6cgFKlT/lQIOOdAAoYwADFjiID3YYEMKNPzZ00mUPbIAA6gAAwA1v5xyo6GSuEkVDSzeCSkAQNonH4J37jBUKZMEwNYmAJyDQAK8JlIoqowgSmxBB6wjiQGcaBTAAqQAIIEAlR0y7LGKqFCdeNx26+234IYr7rjW+cjTWoJKMoEADHgCiruKXIstIlaSa++9+ObLrbk4HYBVVpEoIAACAMALLyH7oMKPQvM2fBR3EEPyWUoACEwwJvshrPDC3TnssUwMoINAtYtMW0oArDUgwAMasSbsqR/HbFADGO0zKCLotlXxKLjGC7PMQNdjmAH+8hf00QA1kE8APVuG9NMEYaKJqMTI/wv11cT0UqrRWHctjQQPtOb12Nys1cABVFf9M9ls16LAAaMIoKzTbddNzKdr3Yzj2nb3Hck5mUTQMd1+F77KRQyoNKXhjFOiuHeNR/4IA6AwwNoBJHfIt+SN6wrAT5/rvdfmnBvuOeigb1X66ojoWgCwr4tui9Wst61rjbLXQnvtZDsQ5e9Sqs778H2RTvzxq+yO/PKQKM/886ZCL/3o01efvPHWZz+I89pDz333zH8Pvt8OSBBA2IyIP37dDgA7SubCYL8+4+dwdNLjrcs/f+Frddd/9Ptj3v/+57MAMk8jYRtFTTSmsJ9s7IEQjKAEJ0jBClrwghjMoAY3yMEOev/wgyDc2ODQErIIYKIBh0gYKhwYQgqysIUNzBAMI/jCGT6whjPEoQ1juEMM4icvBzgJAhb4MsLNTn+PUF8Rc6HEJYoNN1Eyou6Q6IgmWouKTnwLFilhxe9YsYuFAKOatnhF4T2xa18kYwHVRig1rvGMWEujFJnoxjGaEXJorCMAxLg9PcavjXdEjh+1I0c2GnJvgVwc1qKIC0YGw5G7gKQtJKkLSj7DkgbMJGk+hTL8rSJ4ACifLzwJCVFKAH8KYJbbzJc4QnByi6kEBidPuYpXDoKTrawl8AygElOSkhWzRKUqUTOKtRCMF64jRM6OOYllEsIkNqpFaPoBzQKgUBX/0EzFAopJil8+oprX5CYzLUEjtviPLeOsxTY/0c1QnGSQI8EYABDICnQ15AELWIDKRggJfOoTIYOIGxlZ44BMDEJlRLSEQAs2sM8BtBIIJYQ86akK7hggZALghD/32ciGEnChpNFVKkRai4MVQmVpkwRK91iKaJb0HKkQWANUlrFKMA2mAFgnRuY2CZnSdI/RJGkt1sVTAKz0FjpV2vZaCk+kBNWlnxRNIaYFP0hQtWIrEyorKEcthupjFC7raVajuYAJRGZg3myEJ77KLpJqVRUFzehUu4qLsp41JQKjBlQ5c9X6lVSq+ZGbKs6hrNuxxY39Exgo3hoJw2bCF9F0/1ZJRCPSvm5kqIIlBGF1Ma1UOMuxe31MQRtggKNic1r6UIlGGoAKfj5ita313ULkltJlISAAgOOEyh4wCtc+QrZEdUDI2BrWSey2t6MtrVyjutx5CoC1AfCtJYZrALACl7aoYYDKGlBcS+QMoDWSX3jVFFpKOCBuDUCfKEjRXS66NIjPpeJ6E+Ay7T63vZRYS7XGiwv4sjaM5dWkgAdM4AIb+MAITrCCF8zgBjv4wRAuRyqBpwDKJZQeRYswab77iX3UdhxSXYuGSZNKotLEwwAA1QOyUtYC1CQdLE7EPlgWgQXww2UKYMgBenk+f6UiZKx1wFpoXBMJ/ARtI9aLUPx1dc6ZksJsoxJABM5RU2GQgme/ymj7bpsAgtHodew6RwJcbLZRoHBdB9CQdJN8lCUDVMSeSIWIP6syYYF3sQiZVtjOkcpoYiIVIRZAQAWtkQhEl815cfM5GSpnQa9lY3buDmURwmSgRimacQZAoAch4rLGDX2I7oqiHcpoUk9LcA9Yx7RGWOlJ00TKpU1AqTP9XGaJmNQTkADRLhtqUbu00nCO5q0DoDIpz/Oa5JU0nrtj3yHO+qkCUMCtRcw0UlS117OhL7Y554Aqb/vb4A63uMdN7nKb+9zoTre6183udrv73fCOt7znTe962/ve+M63vvfN7377+9/zCgQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients undergoing saphenous vein graft stenting have a lower cumulative probability of survival (upper panel, five-year survival 70.5 versus 93.4 percent) and event-free survival (lower panel, five-year event-free survival 21.1 versus 63.3 percent) compared to patients with stenting of native vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Laham RJ, Carrozza JP, Berger C, et al. J Am Coll Cardiol 1996; 28:820.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20590=[""].join("\n");
var outline_f20_6_20590=null;
var title_f20_6_20591="Secondary hyperfibrinolysis";
var content_f20_6_20591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Secondary hyperfibrinolysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG showing secondary hyperfibrinolysis. The red tracing indicates a normal study.",
"    <br>",
"     This study shows a normal ACT, R time, K time, and alpha angle; high LY30 reflecting hyperfibrinolysis; normal MA and G, reflecting onset of fibrinolysis after achieving maximal clot strength.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_6_20591=[""].join("\n");
var outline_f20_6_20591=null;
